***Curriculum vitae***

|  |  |
| --- | --- |
| **Date Prepared:** | July 15, 2022 |
| **Name:** | Naomi Joan **Winick**, M.D. |
| **Office Address:** | The Universit The University of Texas Southwestern Medical Center at DallasDepartment of Pediatrics 5323 Harry Hines Blvd. Dallas, TX 75390-9063 |
| **Work Phone:**  | 214-456-2382 |
| **Work E-Mail:**  | naomi.**winick**@utsouthwestern.edu |
| **Work Fax:** | 214-456-6133 |
| **Place of Birth:** | United States |

**Education**

|  |  |  |  |
| --- | --- | --- | --- |
| Year | Degree(Honors) | Field of Study(Thesis advisor for PhDs) | Institution |
| 1974 | B.A. | Independent Study | Indiana University  |
| 1978 | M.D. | Medicine | Northwestern University |
| December 2020 | MPH | Public Health | University of Texas Health Science Center |

**Postdoctoral Training**

|  |  |  |  |
| --- | --- | --- | --- |
| Year(s) | Titles | Specialty/Discipline(Lab PI for postdoc research) | Institution |
| 1978-1979 | Internship | Pediatrics | Babies Hospital (Columbia University, NY) |
| 1979-1981 | Resident | Pediatrics | Babies Hospital, NY |
| 1981-1983 | Fellow | Pediatric Hematology and Oncology | Memorial Sloan-Kettering, NY New York Hospital |
| 1982-1983 | Chief Fellow | Pediatric Hematology and Oncology | Memorial Sloan-Kettering Cancer Center, NY  |
| 1983-1984 | Research Fellow | Pediatric Hematology-Oncology | Univ. of Texas Health Science Center at Dallas, TX |
| 2017-2020 | Graduate Student | Master’s Degree in Public Health | University of Texas Health Science Center, Southwestern Medical Center Campus |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

**Current Licensure and Certification**

Licensure

Texas State Board of Examiners

Board and Other Certification

American Board of Pediatrics

American Board of Pediatric Hematology-Oncology

American Board of Hospice and Palliative Care Medicine (expires 2023)

**Honors and Awards**

|  |  |  |
| --- | --- | --- |
| Year | Name of Honor/Award | Awarding Organization |
| 1974 | Phi Beta Kappa | Indiana University |
| 1975 | Community Service Award | Northwestern University |
| 1986 | American Society Clinical Oncology Mead Johnson Clinical Investigator Award | American Society of Clinical Oncology |
| 1987-1990 | American Cancer Society Cancer Career Development Award | American Cancer Society  |
| 1996-Multiple Years | Best Doctor in Dallas | D-Magazine, The Best List |
| 2006 | Wipe Out Kids Cancer Spirit of “Little Mo” Award | Wipe Out Kids Cancer |
| 2014 | Elected to the Alpha Omega Alpha Honor Medical Society | UT Southwestern Medical Students |
| 2019 | George R. Buchanan Award for Teaching | UT Southwestern Fellows in Hematology/Oncology |
| 2020 | President’s Award for Diversity and Humanism in Clinical Medicine | UT Southwestern |

**Faculty Academic Appointments**

|  |  |  |  |
| --- | --- | --- | --- |
| Year(s) | Academic Title | Department | Academic Institution |
| 1984-1985 | Assistant Instructor  | Pediatrics | Univ. of Texas Health Science Center at Dallas, TX |
| 1985 | Assistant Professor | Pediatrics  | UTSWMC at Dallas, TX |
| 1989-1999 | Director | Clinical Oncology | Children's Medical Center, TX |
| 1993 | Associate Professor | Pediatrics  | UTSWMC at Dallas, TX |
| 1998 | Lowe Foundation Professor | Pediatric Neuro-Oncology | Children’s Medical Center ,TX |
| 1999 | Professor with Tenure | Pediatrics | UTSWMC at Dallas, TX\* |

* \*as of 2017 this is a part time position at 30% effort; no longer tenured

**Appointments at Hospitals/Affiliated Institutions**

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  |  |
|  |  |  |  |
| Current |
| 1984-present | Attending Physician | PediatricHematology/Oncology | Children’s Health, Dallas, TexasChildren’s Health, Plano, Texas |
| 1984-present | Attending Physician | Pediatric Hematology/Oncology | Parkland Hospital and UT Southwestern Hospitals, Dallas, Texas |

**Other Professional Positions**

|  |  |  |
| --- | --- | --- |
| 2008-2011 | Advisory Board | Sanofi Aventis  |
| 2008-2010 | Advisory Board  | EUSA Pharmaceuticals |
| 2021-2026 | External Advisory Board  | P20 project, "Improving outcome disparities for Latino children and adolescents with ALL." Co-PIs Rabin, K and Lupo, P |
|  |  |  |

**Major Administrative/Leadership Positions (also see below-National)**

|  |  |  |
| --- | --- | --- |
| Year(s) | Position Title | Institution |
| 2012-217 | Co-Chair Women in Science and Medicine Advisory Committee | UTSWMC, TX |
|  |

**Committee Service**

|  |  |  |
| --- | --- | --- |
| Year(s) | Name of Committee | Institution/Organization |
| UTSW |
| 1998-2001 | Institutional Review Board | UTSWMC, TX |
| 2001-2015 | Promotion and Tenure Committee | UTSWMC, TX |
| 2004-2012 | Simmons Cancer Center Protocol Review Committee |  |
| 2005-2006 | Search Committee for Chair of Dermatology | UTSWMC, TX |
| 2005-2012 | Interviewer, Medical Student Admissions | UTSWMC, TX |
| 2005-2012 | Director, Pediatric Hematology Oncology Grand Rounds | UTSWMC, TX |
| 2005-2012 | Simmons Cancer Center Clinical CancerResearch Committee | UTSWMC, TX |
| 2005-present | Simmons Cancer Center Data Safety & Monitoring Committee | UTSWMC, TX |
| 2006-2013 | Advancement of Women in Medicine Committee | UTSWMC, TX |
| 2009 | Liaison Committee on Medical Education-Educational Resources Subcommittee | UTSWMC, TX |
| 2009 | Clinical Transformation Project Group | UTSWMC, TX |
| 2009-2012 | Faculty Senate | UTSWMC, TX |
| 2009-present | Teaching Awards Committee | UTSWMC, TX |
| 2010 | Search Committee for Chairman of Pathology | UTSWMC, TX |
| 2011 | Committee investigating possible misconduct in scientific research (appointed by the Dean) | UTSWMC, TX |
| 2013-2017 | Post-Tenure Review Committee | UTSWMC, TX |
| 2014-2020 | Administrative and Academic Operations Subcommittee for the Six-Year Plan: 2014-2020 | UTSWMC, TX |
| 2017-present | Member, Women in Science and Medicine Advisory Committee | UTSWMC, TX |
| Hospital |
| 2002-2003 | Medical Executive Committee | Children’s Medical Center, TX |
| 2005-2012 | Director, Pediatric Hematology Oncology Grand Rounds | UTSWMC, TX |
| 2005-2017 | Chemotherapy Safety Task Force | Children’s Medical Center, TX |
| 2012-2017 | Palliative Care Steering Committee | Children’s Medical Center, TX |
|  |  |  |
| State/Regional/National/International |
|  |  |  |
|  |
| 1999-2001 | POG/COG Nominating Committee, UTSWMC, TX, Pediatric Oncology Group/COG | Children’s Oncology Group |
| 2000-present | Children’s Oncology Group ALL Executive Committee | Children’s Oncology Group |
| 2001-2013 | Children’s Oncology Group Voting Body | Children’s Oncology Group |
| 2001-2013  | UTSW for the Children’s Oncology Group Program, Principal Investigator  | Children’s Oncology Group |
| 2002-2007 | Vice-Chair for Clinical Trials, AcuteLymphoblastic Leukemia, COG | Children’s Oncology Group |
| 2002-2007 | Phase I Consortium, UTSW, Principal Investigator | UTSW |
| 2003-2013 | Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee of the Food and Drug Administration  | Food and Drug Administration  |
| 2005 | ASH: FDA Subcommittee on Childhood ALL | Washington, D.C. |
| 2005-2010 | PDQ Pediatric Treatment Editorial Advisory Board | PDQ – National Cancer Institute  |
| 2007-2017 | Chair, Outcomes Subcommittee for ALL, Children’s Oncology Group | Children’s Oncology Group |
| 2008-2012 | Member, Constitutional Review Committee, Children’s Oncology Group | Children’s Oncology Group  |
| 2009 | Liaison Committee on Medical Education-Educational Resources Subcommittee | Liaison Committee on Medical Education |
| 2009-2011 | Cancer Control-Long-Term Survivor and Nursing Consortium Task Force, COG | Children’s Oncology Group |
| 2009-2012 | Member, COG-CureSearch Joint Advocacy Task Force | Children’s Oncology Group |
| 2011-2013 | Member, Real World Protocol Committee, COG | Children’s Oncology Group |
| 2011-2016 | Data Safety Monitoring Board, St. Jude Children’s Research Hospital, member | St. Jude Children’s Research Hospital |
| 2011-2017 | Pediatric Hematology Oncology Sub-Board of the American Board of Pediatrics, member | American Board of Pediatrics |
| 2011-present | Member, Uniform Dosing Committee, COG | Children’s Oncology Group |
| 2011-present | Elected member Hematology/Oncology DisciplineCommittee, COG | Children’s Oncology Group |
| 2013 | Abstract Review Committee | American Society of Hematology  |
| 2014-present | NCI Pediatric Leukemia Lymphoma Steering Committee | National Cancer Institute |
| 2015-2022 | Vice- Chair NCI Pediatric Leukemia Lymphoma Steering Committee  | National Cancer Institute |
| 2015-2020 | Chair, Hematology/Oncology DisciplineCommittee, COG | Children’s Oncology Group |
| 2015-2020 | Treasurer  | COG Foundation |
| 2015-2020 | Member, Executive Committee, COG | Children’s Oncology Group |
| 2021-2026 | PDQ Pediatric Treatment Editorial Advisory Board | PDQ – National Cancer Institute |
| 2022-2027 | Chair, Institutional Performance Review Committee | Children’s Oncology Group |

**Professional Society Memberships**

|  |
| --- |
| American Society of Clinical Oncology, member |
| Pediatric Oncology Group, member |
|  |
| Children’s Oncology Group, member |
| Society for Neuro-Oncology, member |
| American Society Pediatric Hematology Oncology, member |
| International Society of Paediatric Oncology (SIOP), member |
| American Academy of Hospice and Palliative Medicine, member |

**Grant Review Activities**

|  |  |  |
| --- | --- | --- |
| 1994 | Program Project Review Committee | Dana Farber/Harvard Medical School Childhood ALL Program Project Grant |
| 2004 | Program Project Review Committee | Dana Farber/Harvard Medical School Childhood ALL Program Project Grant |
| 2008-present | Grant Reviewer | St. Baldrick’s Foundation |
| 2012 | Grant Reviewer | NIH National Loan Repayment Program |
| 2021-present | Grant Reviewer | CTSA Program at UTSW |

**Editorial Activities**

|  |
| --- |
| Journal of Clinical Oncology |
| Journal of Pediatric Hematology/Oncology |
| Pediatric Blood and Cancer |
| Pediatric Infectious Disease Journal |
| Blood |
| Leukemia |
| Cancer Chemotherapy and Pharmacology |
| Lancet |
| Cancer Research |

**Grant Support**

|  |  |
| --- | --- |
| Past | Lowe Foundation/Southwestern Medical Foundation |
|  | Professorship in Pediatric Neuro-Oncology  |
|  | Principal Investigator  |
|  | 6/14/1995 – 2020, $12,000 annual direct |
|  |  |
|  |  |
|  |  |
|  | Temple Hoyne Buell Foundation  |
|  | To Children’s Medical Center for Naomi **Winick** |
|  | 1999-$30,000; 2000-$55,000; 2001-$30,000; 2002-$26,000; 2003-$40,000;2004-$40,000; 2005-$40,000; 2006-$45,000; 2007-$45,000; 2008-$50,000; 2009-$50,000; 2010-$50,000; 2011-$50,000; 2012-$50,000; 2013-$50,000; 2014; $50,000; 2015 $50,000; 2016 $50,000; 2017 $50,000 |
|  |  |
|  |  |
|  | Micaela’s Army |
|  | Principal Investigator |
|  | 9/25/2017- open, $24,000 total |
|  |  |
|  |  |
|  | Wipe Out Kid’s Cancer |
|  | Principal Investigator |
|  | 3/01/2017- open, $53,397 total |
|  |  |
|  |  |
|  | St. Baldrick’s  |
|  | Principal Investigator |
|  | 7/01/2017- 6/30/2018, $47,742 total |
|  |  |

|  |  |
| --- | --- |
|  | NCI/ Children’s Oncology Group |
|  | Children’s Oncology Group “Evaluation of Methotrexate Related Neurotoxicity”  |
|  | Principal Investigator of Subcontract |
|  | 3/1/2006 – 2/28/2013. $210,000 annual direct |
|  |  |
|  |  |
|  | NCI/ Children’s Oncology Group |
|  | Children’s Oncology Group Chair’s Grant |
|  | Principal Investigator of Multiple Subcontracts |
|  | 3/1/2003 – 2/28/2013 $98,000 annual direct  |
|  | Plus $80,000 DC annually for patient accruals |
|  |  |
|  |  |
|  | NCI/ Children’s Oncology Group |
|  | COG Phase I/Pilot Consortium  |
|  | Principal Investigator of Multiple Subcontracts |
|  | 8/8/2002 – 7/31/2012. $12,000 annually for patient accruals  |
|  |  |
|  |  |
|  | NCI/ Children’s Oncology Group |
|  | Children’s Oncology Group “Protocol ADVL0911”  |
|  | Principal Investigator of Subcontract  |
|  | 6/1/2009 – 5/31/2011, $22,465 |
|  |  |
|  |  |
|  | NCI/ Children’s Oncology Group |
|  | Children’s Oncology Group “Protocol ADVL0813”  |
|  | Principal Investigator of Subcontract |
|  | 6/1/2009 – 5/31/2011, $25,371 direct |
|  |  |
|  | NCI/ Children’s Oncology Group |
|  | Children’s Oncology Group “Protocol ANBL0931”  |
|  | Principal Investigator of Subcontract |
|  | 6/1/2009 – 5/31/2011, $36,507 direct |
|  |  |
|  | Timberlawn Psychiatric Research Foundation, Inc. |
|  | A Randomized Evaluation of a Six-Week Grief Curriculum for Bereaved Parents: Bereavement support for family of children who died of cancer |
|  | Principal Investigator |
|  | 9/1/2014 – 8/31/2015 $21,071 |
|  |  |
|  | Leukemia Texas Grant  |
|  | The Feasibility and Acceptability of Incorporating Electronic Assessment Tools during  |
|  | Outpatient Visits for Patients in the Maintenance Phase of Therapy for Acute Lymphoblastic Leukemia |
|  | 6/15/2014-6/15/2015 $5000 |
|  |  |

**Clinical Trials Activities**

|  |  |
| --- | --- |
| 2010 | Children’s Oncology Group |
|  | *Protocol AALL0932 Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)*Committee Member |
|  |  |
| 2012 | *Protocol AALL1131 A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum*Committee Member |
|  |  |
| 2013 | *2013 Protocol ACCL10P1Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study*Committee Member |
|  |  |

|  |  |
| --- | --- |
| Past |  |
| 1986-2001 | Member of 14 Pediatric Oncology Group Study Committees; titles and lists available on request. Also a member of the ALL and Developmental Therapeutics Steering Committees |
|  |  |
| 1992-1995 | Pediatric Oncology Group 9202, UTSWMC  |
|  | *A Pilot Study of IV-6-MP for Patients with Standard Risk ALL* |
|  | Chair |
|  |  |
| 1998-2002  | Pediatric Oncology Group 9705, UTSWMC |
|  | *ALinC 17: Protocol for Patients with Newly Diagnosed Standard Risk ALL: A* *POG Pilot Study* |
|  | Study Chair |
|  |  |
| 2000-2005 | Pediatric Oncology Group 9905 Study Committee, UTSWMC |
|  | *ALinC 17: Protocol for Patients with Newly Diagnosed Standard Risk ALL: A* *Phase III Study* |
|  | Study Chair |
|  |  |
| 2000-2005 | Pediatric Oncology Group 9904 Study Committee, UTSWMC |
|  | *ALinC 17: Protocol for Patients with Newly Diagnosed Lower Risk ALL: A* *Phase III Study* |
|  | Committee Member  |
|  |  |
| 2000-2005 | Pediatric Oncology Group 9906 Study Committee, UTSWMC |
|  | *ALinC 17: Protocol for Patients with Newly Diagnosed High Risk ALL:* *Evaluation of the Augmented BFM Regimen-A Phase III Study* |
|  | Committee Member |
|  |  |
| 2002-2007 | Acute Lymphoblastic Leukemia, COG |
|  | Vice-Chair for Clinical Trials |
|  |  |
| 2001-2013 | UTSW for the Children’s Oncology Group Program |
|  | Principal Investigator  |
|  |  |
| 2002-2007 | UTSW |
|  | *Phase I Consortium* |
|  | Principal Investigator |
|  |  |
| 2003 | Children’s Oncology Group, AALL03B1 Study Committee |
|  | *Classification of Acute Lymphoblastic Leukemia* |
|  | Committee Member  |
|  |  |
| 2003 | Children’s Oncology Group, AALL0232 Study Committee |
|  | *Higher Risk B-precursor ALL* |
|  | Committee Member |
|  |  |
| 2003 | Children’s Oncology Group AALL0331 Study Committee |
|  | *Post-induction intensification for children with standard risk acute lymphoblastic* *Leukemia* |
|  | Committee Member  |
|  |  |
| 2005 | Children’s Oncology Group, AALL0433 Study Committee |
|  | *Therapy for “Intermediate Risk” relapse of B-precursor acute lymphoblastic leukemia* |
|  | Committee Member  |
|  |  |
| 2005 | Children’s Oncology Group, AALL0434 Study Committee |
|  | *Intensified Methotrexate, Nelarabine (Compound 506U78; IND # 52611) and* *Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell* *Acute Lymphoblastic Leukemia* |
|  | Committee Member  |
|  |  |
| 2005 | Children’s Oncology Group, AALL03N1 Study Committee |
|  | *Understanding the Racial and Ethnic Differences in Survival in Children with ALL* |
|  | Committee Member  |
|  |  |
| 2007 | Children’s Oncology Group, AALL06N1 Study Chair |
|  | *A study of neurocognitive function in children treated for acute lymphoblastic leukemia* |
|  |  |
| 2007 | Children’s Oncology Group, AALL0631 Study Committee |
|  | *A Study of Risk Directed Therapy for Infants with ALL: Randomization of Highest Risk* *Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND* *#76431)* |
|  | Committee Member  |
|  |  |
| 2007 | Children’s Oncology Group, AALL0622 Study Committee |
|  | *Intensified tyrosine kinase inhibitor therapy in Philadelphia chromosome positive-acute* *lymphoblastic leukemia* |
|  | Committee Member  |
|  |  |
| 2007 | Children’s Oncology Group, AALL07P4 Study Committee |
|  | *A Pilot Study of Intravenous EZN-2285 (SC-PEG E. coli L-asparaginase, IND# 100594)* *or Intravenous Oncaspar® in the Treatment of Patients with High-Risk Acute* *Lymphoblastic Leukemia* |
|  | Committee Member  |
|  |  |
| 2008 | Children’s Oncology Group, AALL08P1 Study Committee |
|  | *Intensified PEG-Asparaginase in High Risk Acute Lymphoblastic Leukemia: A Pilot* *Study* |
|  | Committee Member  |
|  |  |
| 2008 | Children’s Oncology Group, AALL07P1 Study Committee |
|  | *A Phase Ib/II Trial of Bortezomib (PS-341, Velcade®) in Combination with Intensive* *Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL)* |
|  | Committee Member  |
|  |  |
| 2008 | Children’s Oncology Group, AALL02P2 Study Committee |
|  | *Treatment of Late Isolated Extramedullary Relapse from Acute Lymphoblastic Leukemia* *(ALL) (Initial CR1 > 18 months)* |
|  | Committee Member  |
|  |  |
| 2008-2010 | ADVL08N1: *A Pharmacokinetic Questionnaire Participation Study* |
|  | Vice Chair  |
| 2012-2014 | *Therapeutic Advances in Childhood Leukemia and Lymphoma (ACL)*  |
|  | Local P.I. |

**Teaching Activities**

|  |  |
| --- | --- |
| Year(s) | Activity |
| Medical and graduate school didactic and small group teaching |
| 2009-present | Mentor, Sprague College at UTSWMC |
|  |  |
| Dissertation committees |
| 1993 | Lorene Knowles, Ph.D.: awarded in 1993, “Childhood Leukemia: Individual and Familial Psychological Adjustment”. Doctoral Dissertation Committee member |
| 1998 | Jennifer Niskala, Ph.D.: awarded in 1998, “Neuropsychological Sequela of Oral Methotrexate Treatment for Childhood Leukemia”, Doctoral Dissertation Committee member |
| 2017 | Ana El-Behadi: “The Feasibility and Efficacy of Incorporating Motivational Interviews for Parents and/or Teens during the Maintenance Phase of Leukemia Therapy |
|  |
| Qualifying examination committees |
|  |  |
|  |  |
| Committees concerned with medical and graduate student education |
| 2009 | Liaison Committee on Medical Education-Educational Resources Subcommittee, UTSWMC |  |
|  |  |  |
| Graduate student rotations |
|  |  |
|  |  |
| Medical student rotations |
| 2007 | Rachna Rai, M.D.: UT Southwestern Medical School, recipient of the Kurt Ian Wey award in Pediatrics 2008; Pediatric Internship and Residency at Duke University 2008-2011; General Pediatrics at Oklahoma University Medical Center |
| 2015 | Amy Wu: UT Southwestern Medical School; funded summer project designed to determine the role of age in the toxicities experienced by patients receiving therapy for high risk ALL-a retrospective chart review; Graduated from UTSW 2018, Pediatric Internship and Residency at University of Michigan 2018-2021 |
| 2020 | Kaley Desher: Evaluating Cardiac Toxicity of COG protocols AAML0531 and AAML1031; co-mentoring with Dr. Kelly Getz, University of Pennsylvania, Children’s Hospital of Philadelphia |
| Graduate student trainees |
| 2015 | Melissa Carawan, thesis committee for her Masters in Psychology |
|  |  |
| Postgraduate medical education (graduate & continuing medical education) |
|  |  |
| Postdoctoral trainees |
| 2004-2007 | Tamra Slone, M.D.: Fellow 2004-2007; ASH sponsored Clinical Research Training Institute 2006-2007; ASCO Young Investigator Award 2007; K12 sponsored Master in Clinical Training 2007-2010; Assistant Professor, 2008-2018, Associate Professor UTSW, 2019-present  |
| 2004-2007 | Jennifer Wright, M.D.: Fellow 2004-2007; Assistant Professor University of Utah, 2007 |
| 2006-2009 | Kenneth Chen, M.D.: Pediatric Intern and Resident 2006-2009; Hospitalist Childrens Medical Center, 2009-2010; Pediatric Heme/Onc fellowship at UTSWMC, July 2010-2014; Assistant Professor of Pediatrics and the Children’s Medical Center Research Institute at UTSW 2015-present |
| 2006-2009 | Martha Stegner, M.D.: Scholarly Oversight Committee Member: Fellow 2006-2009; Assistant Professor, UTSWMC 2009-present |
| 2006-2009 | Laura Klesse, MD, Ph.D.: Scholarly Oversight Committee member: Fellow 2006-2009; Assistant Professor, UTSWMC 2009-2017; Associate Professor; Dedman Family Scholar in Clinical Care 2018-present |
| 2008-2010 | Hanumatha Pokola, M.D.: Fellow 2008-2010; Pediatric Hematology/Oncology University of Oklahoma |
| 2009-2010 | Monica Ardura, D.O.: Fellow in Infectious Disease, K12 sponsored Master in Clinical Training (I was her sponsor only from 2009-2010); Assistant Professor, UTSWMC 2010; Infectious Disease faculty Nationwide Childrens Hospital, Medical Director of the Host Defense Program, Associate Professor Ohio State University-present |
| 2009-2011 | Amy Fowler Tellinghuisen, M.D., Fellow 2009-2011: Awarded Best Poster Presentation; Senior Fellow Annual Research Day; Accepted student Outcomes Seminar Childrens Medical Center; Staff Dell Childrens Hospital, Austin TX October 2011-Adjunct Clinical Faculty appointment UTSW; Pediatric Hematology/Oncology University of Washington, Seattle Children’s Hospital |
| 2011-2012 | Shannon Mitchell, MD: Senior Resident, 2011-2012; Pediatric Heme/Onc Fellowship 2012-2015; Pediatric Hematology Oncology Dell Children’s Hospital |
| 2010-present | Rachael Thienprayoon (Chesley), MD: Fellow July 2010-June 2013; grant awarded through the St. Baldrick's Foundation 2011-2013.  Accepted to the Clinical Research Training Institute sponsored by the American Society of Hematology; accepted for a fellowship in Pediatric Palliative and Hospice Medicine, July 2013- June 2014. Currently an Assistant Professor of Anesthesia and Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati. 2015 Yong Investigator Award from the American Academy of Pediatrics, section on Hospice and Palliative Care; Co-Mentor Sojourn Scholar Leadership Program Grant, July 2020-2023 |
|  |  |
| 2010-2015 | Kasey Leger, MD: Fellow, July 2010-present; accepted to the American Association of Cancer Research/American Society of Clinical Oncology Workshop: Methods in Clinical Cancer Research; ASCO Young Investigator Grant Award; Childrens Cancer Fund Grant award, July 2014-Assistant Professor University of Washington, Seattle Children’s Hospital |
| 2016-2019 | Raul Montiel-Esparza, MD: Pediatric Resident; accepted to the Ped Heme/Onc Fellowship Program at Stanford beginning July 2019 |
| March 2021-present | Melanie Stall, MD: Fellow July 2020-present |

**Invited Lectures**

|  |  |  |
| --- | --- | --- |
| Year(s) | Title | Location |
| International |
| 1996 | Visiting Professor, McGill Comprehensive Cancer Center and Universite de Montreal | Montreal, Canada |
| 1996 | Pediatric Oncology Group Ontario (POGO) *Neurotoxocity in ALL Survivors* | Ontario, Canada |
|  |  |  |
| National |
| 2000 | CTEP Symposium on Ascending Neuropathy Following Intrathecal Chemotherapy *Pediatric Oncology Group Experience with Ascending Neuropathy* | Bethesda, MD |
| 2003 | FDA Drug Advisory Committee *Perspective* Bethesda, Maryland July 2003*of Children's Oncology Group on the use of 6-Mercaptopurine* | Bethesda, MD |
| 2003 | Ponte di Lengo Meeting, *Infant Leukemia*  | San Diego, CA |
| 2004 | Grand Rounds, St. Jude Children’s Research Hospital, *COG Approach to All*  | Memphis, TN |
| 2004 | ASCO, Meet the Professor Session New Orleans, LA June 2004ASHPO board review course presentation, *Your Career as a Clinical Researcher* | New Orleans, LA |
| 2005 | Children’s Oncology Group, *Future Randomized Trials* | Los Angeles, CA |
| 2005 | ASH: FDA Subcommittee on Childhood ALL | Washington, DC |
| 2006 | ASHPO board review course presentation, *Acute**Lymphoblastic Leukemia* | Chicago, IL |
| 2007 | American Society of Neuroradiology 45th Ann Mtg Chicago, IL; June 13, 2007 *Neurotoxicities Associated with Childhood Malignancy* | Chicago, IL |
| 2007 | 9th Annual SW Pediatric & Neonatal Heme-Onc for Albuquerque, NM; October 05, 2007The Practitioner *“Leukemias: Where Are We Now & Where Are We Going?”* | Albuquerque, NM |
| 2008 | 21st ASPHO Annual Meeting Cincinnati, OH; June 2008*Children’s Oncology Group Acute Lymphoblastic* *Leukemia Trail Strategy: Past, Present and Future* | Cincinnati, OH |
| 2009 | Chemotherapy Foundation Symposium XXVII New York, NY November 2009Innovative Cancer Therapy for Tomorrow*Update: Acute Lymphoblastic Leukemia* | New York, NY |
| 2010 | St Jude Childrens Research Hospital Memphis, TN; May 2010Seminar: *6-Mercaptopurine in Childhood ALL* | Memphis, TN |
| 2010 | Vanderbilt University Nashville, TN November 2010Pediatric Oncology Rounds*Overview of Childrens Oncology Group Protocols**For Acute Lymphoblastic Leukemia* | Nashville, TN |
| 2012 | St. Baldrick’s Advisory Board | New York, NY |
| 2014 | Childrens Oncology Group Investigators Lunch*The Significance of CNS2 Status at Diagnosis of Acute Lymphoblastic Leukemia* | Dallas, TX |
| 2015 | Pediatric Heme/Onc Grand Rounds National Childrens Hospital | Washington, DC |
| 2015 | Recommendations for the treatment of children with acute lymphoblastic leukemia and CNS disease at diagnosis | San Francisco, CA |
| 2019 | Grand Rounds, Children’s Hospital and Research Center at Oakland, June 2019 *The Treatment of Childhood Acute Lymphoblastic Leukemia*  | Oakland, CA |
| 2019 | Pediatric Heme/Onc Grand Rounds, Children’s Hospital and Research Center at Oakland, June 2019 *CNS Protection and Toxicity* | Oakland, CA |
| Regional/Local (Lectures to fellows (~10/year 2010 -present not listed) |
| 1999 | Grand Rounds, Children’s Medical Center  | Dallas, TX |
| 2004 | Scott Storm Lecture | Dallas, TX |
| 2005 | Pediatric Interest Group, UTSW  | Dallas, TX |
| 2005 | Tejas Council Senior Girl Scouts Career Exploration | Dallas, TX |
| 2005 | Grand Rounds, Children’s Medical Center | Dallas, TX |
| 2005 | Clinical Genetics Grand Rounds, UTSW | Dallas, TX |
| 2007 | Aware for All: Clinical Research Education Day | Dallas, TX |
| 2007 | Clinical Research Education and Awareness Day | Dallas, TX |
| 2008 | Scott Storm Pediatric and Adult Hematology-OncologyNursing Seminar *Closing the Gap: Defining the* *Treatment of the Young Adult with Acute Lymphoblastic Leukemia (ALL)* | Dallas, TX |
| 2009 | Texas Forum on Blood Cancers Dallas, TX; February 28, 2009*New and Emerging Therapies for Pediatric Patients* | Dallas, TX |
| 2010 | Grand Rounds, Children’s Medical Center  | Dallas, TX |
| 2010 | Cooks Childrens Hospital | Fort Worth, TX |
| 2010 | Grand Rounds, Pediatric Hematology-Oncology Dallas, TX; November 2010*New Leukemia Trials* | Dallas, TX |
| 2011 | Simmons Cancer Center, Hematologic Malignancies Retreat at UTSW Dallas, TX; January 2011 | Dallas, TX |
| 2012 | Clinical Research: Raising the Bar *Investigator Challenges and Responsibilities* | Dallas, TX |
| 2010-2015 (annual presentation) | Demystifying the Promotion & Tenure Process Symposium*The Clinical Scholar Track* | Dallas, TX |
| 2012 | Pediatric Hematology Oncology Grand Rounds*Dexrazoxane* | Dallas, TX |
| 2013 | Pediatric Hematology Oncology Grand Rounds*ALL Update* | Dallas, TX |
| March 16, 2022 | Keynote Speaker- Gold Humanism Honor Society UT Southwestern Medical School Pinning Ceremony Class of 2022 & 2023*Listen* | Dallas, TX |

**Technological and Other Scientific Innovations**

|  |
| --- |
| Innovation |
| Patent, if any, pending or awarded /If described in print/on web, provide citation |

**Service to the Community**

|  |  |  |
| --- | --- | --- |
| 2002-2008 | Advisory Board | Camp SOL |
| 2004-present | Advisory Board | Children’s Cancer Fund |
| 2005-2011 | Contributor | People Living with Cancer |
| 2012-present | Medical Director | Camp SOL |
| 2017, 2018, 2022, 2023 | Volunteer Faculty | United to Serve |

**Bibliography**

Original Research Articles

1. **Winick**, N., P.G. Steinherz, and D.R. Miller, *Terminal deoxynucleotidyl transferase activity in childhood leukemia.* Cancer, 1985. **55**(9): p. 1943-7.

2. Kamen, B.A. and N. **Winick**, *Analysis of methotrexate polyglutamate derivatives in vivo.* Methods Enzymol, 1986. **122**: p. 339-46.

3. Pratt, C.B., B.A. Kamen, N. **Winick**, P. Sartain, J.E. Champion, A.H. Ragab, and M.P. Goren, *Phase I study of iproplatin in pediatric patients: a Pediatric Oncology Group Study.* Cancer Treat Rep, 1987. **71**(1): p. 87-8.

4. Tan, C.T., C. Hancock, P. Steinherz, D.M. Bacha, L. Steinherz, E. Luks, N. **Winick**, P. Meyers, A. Mondora, E. Dantis, and et al., *Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.* Cancer Res, 1987. **47**(11): p. 2990-5.

5. **Winick**, N.J., B.A. Kamen, F.M. Balis, J. Holcenberg, C.M. Lester, and D.G. Poplack, *Folate and methotrexate polyglutamate tissue levels in rhesus monkeys following chronic low-dose methotrexate.* Cancer Drug Deliv, 1987. **4**(1): p. 25-31.

6. **Winick**, N.J., B.A. Kamen, A. Streckfuss, J. Craig, F. McGuirt, R.L. Capizzi, F. Sklar, and D. Coln, *Methotrexate (MTX) concentration in tumors following low-dose MTX.* Cancer Chemother Pharmacol, 1987. **20**(1): p. 78-80.

7. Kamen, B.A. and N.J. **Winick**, *High dose methotrexate therapy: insecure rationale?* Biochem Pharmacol, 1988. **37**(14): p. 2713-5.

8. Rudy, J.L., J.C. Argyle, N. **Winick**, and P. Van Dreal, *HPLC analysis of 6-mercaptopurine and metabolites in extracellular body fluids.* Ann Clin Biochem, 1988. **25 ( Pt 5)**: p. 504-9.

9. **Winick**, N., G.R. Buchanan, S.B. Murphy, A. Yu, and J. Boyett, *Deoxycoformycin treatment for childhood T-cell acute lymphoblastic leukemia early in second remission: a Pediatric Oncology Group Study.* Med Pediatr Oncol, 1988. **16**(5): p. 327-32.

10. Crist, W., J. Boyett, J. Jackson, T. Vietti, M. Borowitz, A. Chauvenet, N. **Winick**, A. Ragab, D. Mahoney, D. Head, and et al., *Prognostic importance of the pre-B-cell immunophenotype and other presenting features in B-lineage childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study.* Blood, 1989. **74**(4): p. 1252-9.

11. Winick N, Bowman W, Arencibia-Mireles O, Kamen BA:  *Prolonged intensive oral methotrexate does not induce its own malabsorption.*  Cancer Chemother Control 1990;1:245-250.

12. Castleberry, R.P., J.J. Shuster, G. Altshuler, E.I. Smith, R. Nitschke, N. **Winick**, N. McWilliams, V. Joshi, and F.A. Hayes, *Infants with neuroblastoma and regional lymph node metastases have a favorable outlook after limited postoperative chemotherapy: a Pediatric Oncology Group study.* J Clin Oncol, 1992. **10**(8): p. 1299-304.

13. Felix, C.A., C.C. Kappel, T. Mitsudomi, M.M. Nau, M. Tsokos, G.D. Crouch, P.D. Nisen, N.J. **Winick**, and L.J. Helman, *Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma.* Cancer Res, 1992. **52**(8): p. 2243-7.

14. Kuerbitz, S.J., C.I. Civin, J.P. Krischer, Y. Ravindranath, C.P. Steuber, H.J. Weinstein, N. **Winick**, A.H. Ragab, M.V. Gresik, and W.M. Crist, *Expression of myeloid-associated and lymphoid-associated cell-surface antigens in acute myeloid leukemia of childhood: a Pediatric Oncology Group study.* J Clin Oncol, 1992. **10**(9): p. 1419-29.

15. **Winick**, N.J., W.P. Bowman, B.A. Kamen, E.S. Roach, N. Rollins, D. Jacaruso, and G.R. Buchanan, *Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia.* J Natl Cancer Inst, 1992. **84**(4): p. 252-6.

16. Felix, C.A., N.J. **Winick**, M. Negrini, W.P. Bowman, C.M. Croce, and B.J. Lange, *Common region of ALL-1 gene disrupted in epipodophyllotoxin-related secondary acute myeloid leukemia.* Cancer Res, 1993. **53**(13): p. 2954-6.

17. Mustafa, M.M., S.D. Weitman, N.J. **Winick**, W.J. Bellini, C.F. Timmons, and J.D. Siegel, *Subacute measles encephalitis in the young immunocompromised host: report of two cases diagnosed by polymerase chain reaction and treated with ribavirin and review of the literature.* Clin Infect Dis, 1993. **16**(5): p. 654-60.

18. Niemann, T.H., M.E. Trigg, N. **Winick**, and G.D. Penick, *Disseminated adenoviral infection presenting as acute pancreatitis.* Hum Pathol, 1993. **24**(10): p. 1145-8.

19. Squires, R.H., Jr., A.G. Weinberg, R.J. Zwiener, and N. **Winick**, *Langerhans' cell histiocytosis presenting with hepatic dysfunction.* J Pediatr Gastroenterol Nutr, 1993. **16**(2): p. 190-3.

20. **Winick**, N., G.R. Buchanan, and B.A. Kamen, *Secondary acute myeloid leukemia in Hispanic children.* J Clin Oncol, 1993. **11**(7): p. 1433.

21. **Winick**, N.J., R.W. McKenna, J.J. Shuster, N.R. Schneider, M.J. Borowitz, W.P. Bowman, D. Jacaruso, B.A. Kamen, and G.R. Buchanan, *Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide.* J Clin Oncol, 1993. **11**(2): p. 209-17.

22. **Winick**, N.J., S.D. Smith, J. Shuster, S. Lauer, M.D. Wharam, V. Land, G. Buchanan, and G. Rivera, *Treatment of CNS relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study.* J Clin Oncol, 1993. **11**(2): p. 271-8.

23. Bernini, J.C., D.W. Fort, M. Pritchard, B.B. Rogers, and N.J. **Winick**, *Adjuvant chemotherapy for treatment of unresectable and metastatic angiomatoid malignant fibrous histiocytoma.* Cancer, 1994. **74**(3): p. 962-4.

24. Griffin, T.C., W.P. Bowman, N.J. **Winick**, and G.R. Buchanan, *Treatment of advanced stage diffuse, small non-cleaved cell lymphoma in childhood: further experience with total therapy B.* Med Pediatr Oncol, 1994. **23**(5): p. 393-9.

25. Mustafa, M.M., A. Pappo, J. Cash, N.J. **Winick**, and G.R. Buchanan, *Aerosolized pentamidine for the prevention of Pneumocystis carinii pneumonia in children with cancer intolerant or allergic to trimethoprim/sulfamethoxazole.* J Clin Oncol, 1994. **12**(2): p. 258-61.

26. Weitman, S.D., N.J. **Winick**, and B.A. Kamen, *"Above all do no harm:" horizons in pediatric oncology.* Curr Opin Pediatr, 1994. **6**(2): p. 219-23.

27. Felix, C.A., M.R. Hosler, N.J. **Winick**, M. Masterson, A.E. Wilson, and B.J. Lange, *ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children.* Blood, 1995. **85**(11): p. 3250-6.

28. Felix, C.A., M.R. Hosler, D. Provisor, K. Salhany, E.A. Sexsmith, D.J. Slater, N.K. Cheung, N.J. **Winick**, E.A. Strauss, R. Heyn, B.J. Lange, and D. Malkin, *The p53 gene in pediatric therapy-related leukemia and myelodysplasia.* Blood, 1996. **87**(10): p. 4376-81.

29. Lowichik, A., J.C. Bernini, V. Tonk, M.Q. Ansari, N.K. Rollins, N.J. **Winick**, and C.F. Timmons, *Relapse of precursor B-cell acute lymphoblastic leukemia as an isolated central nervous system mass lesion 9 years after initial diagnosis.* Med Pediatr Oncol, 1996. **26**(2): p. 129-34.

30. Smith, A., M. Hum, N.J. **Winick**, and B.A. Kamen, *A case for the use of aminopterin in treatment of patients with leukemia based on metabolic studies of blasts in vitro.* Clin Cancer Res, 1996. **2**(1): p. 69-73.

31. Tubergen, D.G., C.F. Stewart, C.B. Pratt, W.C. Zamboni, N. **Winick**, V.M. Santana, Z.A. Dryer, J. Kurtzberg, B. Bell, H. Grier, and T.J. Vietti, *Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study.* J Pediatr Hematol Oncol, 1996. **18**(4): p. 352-61.

32. **Winick**, N., J.J. Shuster, W.P. Bowman, M. Borowitz, A. Farrow, D. Jacaruso, G.R. Buchanan, and B.A. Kamen, *Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia.* J Clin Oncol, 1996. **14**(10): p. 2803-11.

33. Farrow, A.C., G.R. Buchanan, R.J. Zwiener, W.P. Bowman, and N.J. **Winick**, *Serum aminotransferase elevation during and following treatment of childhood acute lymphoblastic leukemia.* J Clin Oncol, 1997. **15**(4): p. 1560-6.

34. Hum, M.C., A.K. Smith, R.H. Lark, N.J. **Winick**, and B.A. Kamen, *Evidence for negative feedback of extracellular methotrexate on blasts of acute lymphoblastic leukemia in vitro.* Pharmacotherapy, 1997. **17**(6): p. 1260-6.

35. Mustafa, M.M., N.J. **Winick**, and L.R. Margraf, *Epstein-Barr virus lymphoproliferative disorder in children with leukemia: case report and review of the literature.* J Pediatr Hematol Oncol, 1997. **19**(1): p. 77-81.

36. Sandler, E.S., D.J. Friedman, M.M. Mustafa, N.J. **Winick**, W.P. Bowman, and G.R. Buchanan, *Treatment of children with epipodophyllotoxin-induced secondary acute myeloid leukemia.* Cancer, 1997. **79**(5): p. 1049-54.

37. Weitman, S., S. Ochoa, J. Sullivan, J. Shuster, N. **Winick**, C. Pratt, T. Vietti, and M. Harris, *Pediatric phase II cancer chemotherapy trials: a Pediatric Oncology Group study.* J Pediatr Hematol Oncol, 1997. **19**(3): p. 187-91.

38. Felix, C.A., A.H. Walker, B.J. Lange, T.M. Williams, N.J. **Winick**, N.K. Cheung, B.D. Lovett, P.C. Nowell, I.A. Blair, and T.R. Rebbeck, *Association of CYP3A4 genotype with treatment-related leukemia.* Proc Natl Acad Sci U S A, 1998. **95**(22): p. 13176-81.

39. Kamen, B.A., N. **Winick**, and J.S. Holcenberg, *Oral versus intravenous methotrexate: another opinion.* J Clin Oncol, 1998. **16**(6): p. 2283-5.

40. Mahgoub, N., R.I. Parker, M.R. Hosler, P. Close, N.J. **Winick**, M. Masterson, K.M. Shannon, and C.A. Felix, *RAS mutations in pediatric leukemias with MLL gene rearrangements.* Genes Chromosomes Cancer, 1998. **21**(3): p. 270-5.

41. Mahoney, D.H., Jr., J. Shuster, R. Nitschke, S.J. Lauer, N. **Winick**, C.P. Steuber, and B. Camitta, *Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial.* J Clin Oncol, 1998. **16**(1): p. 246-54.

42. Mahoney, D.H., Jr., J.J. Shuster, R. Nitschke, S.J. Lauer, C.P. Steuber, N. **Winick**, and B. Camitta, *Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.* J Clin Oncol, 1998. **16**(5): p. 1712-22.

43. Mustafa, M.M., G.R. Buchanan, N.J. **Winick**, G.H. McCracken, I. Tkaczewski, M. Lipscomb, Q. Ansari, and M.S. Agopian, *Immune recovery in children with malignancy after cessation of chemotherapy.* J Pediatr Hematol Oncol, 1998. **20**(5): p. 451-7.

44. Ratliff, A.F., J. Wilson, M. Hum, M. Marling-Cason, K. Rose, N. **Winick**, and B.A. Kamen, *Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies.* J Clin Oncol, 1998. **16**(4): p. 1458-64.

45. Bernstein, M.L., S. Baruchel, S. Devine, N. Markoglou, I.W. Wainer, M. Williams, S. Blaney, A. Moghrabi, N. **Winick**, and T. Vietti, *Phase I and pharmacokinetic study of CI-980 in recurrent pediatric solid tumor cases: a Pediatric Oncology Group study.* J Pediatr Hematol Oncol, 1999. **21**(6): p. 494-500.

46. Keljo, D.J., A.G. Weinberg, N. **Winick**, and G. Tomlinson, *Rectal cancer in an 11-year-old girl with hyperplastic polyposis.* J Pediatr Gastroenterol Nutr, 1999. **28**(3): p. 327-32.

47. Mantadakis, E., L. Herrera, P.J. Leavey, R.O. Bash, N.J. **Winick**, and B.A. Kamen, *Fractionated cyclophosphamide and etoposide for children with advanced or refractory solid tumors: a phase II window study.* J Clin Oncol, 2000. **18**(13): p. 2576-81.

48. Woo, M.H., J.J. Shuster, C. Chen, R.O. Bash, F.G. Behm, B. Camitta, C.A. Felix, B.A. Kamen, C.H. Pui, S.C. Raimondi, N.J. **Winick**, M.D. Amylon, and M.V. Relling, *Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies.* Leukemia, 2000. **14**(2): p. 232-7.

 49. Lauer, S.J., J.J. Shuster, D.H. Mahoney, Jr., N. **Winick**, S. Toledano, L. Munoz, G. Kiefer, J.D. Pullen, C.P. Steuber, and B.M. Camitta, *A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial.* Leukemia, 2001. **15**(7): p. 1038-45.

 50. Liu, L., N. Vapiwala, L.K. Munoz, N.J. **Winick**, S. Weitman, L.C. Strauss, L.S. Frankel, and D.I. Rosenthal, *A phase I study of cranial radiation therapy with concomitant continuous infusion paclitaxel in children with brain tumors.* Med Pediatr Oncol, 2001. **37**(4): p. 390-2.

 51. Molmenti, E.P., D. Nagata, J. Roden, R. Squires, H. Molmenti, D. Casey, C. Fasola, M.J. Lopez, N. **Winick**, W. McPhail, L. D'Amico, R. Goldstein, M. Levy, C. Fasola, J. Andersen, and G. Klintmalm, *Incidence, management, and outcome of posttransplant lymphoproliferative disease in pediatric liver transplant recipients.* Transplant Proc, 2001. **33**(1-2): p. 1727.

 52. Molmenti, E.P., D.E. Nagata, J.S. Roden, R.H. Squires, H. Molmenti, C.G. Fasola, N. **Winick**, G. Tomlinson, M.J. Lopez, L. D'Amico, H.L. Dyer, A.C. Savino, E.Q. Sanchez, M.F. Levy, R.M. Goldstein, J.A. Andersen, and G.B. Klintmalm, *Post-transplant lymphoproliferative syndrome in the pediatric liver transplant population.* Am J Transplant, 2001. **1**(4): p. 356-9.

 53. Blanco, J.G., M.J. Edick, M.L. Hancock, N.J. **Winick**, T. Dervieux, M.D. Amylon, R.O. Bash, F.G. Behm, B.M. Camitta, C.H. Pui, S.C. Raimondi, and M.V. Relling, *Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies.* Pharmacogenetics, 2002. **12**(8): p. 605-11.

 54. Mantadakis, E., A.K. Smith, L. Hynan, N.J. **Winick**, and B.A. Kamen, *Methotrexate polyglutamation may lack prognostic significance in children with B-cell precursor acute lymphoblastic leukemia treated with intensive oral methotrexate.* J Pediatr Hematol Oncol, 2002. **24**(8): p. 636-42.

 55. Marina, N.M., D. Cochrane, E. Harney, K. Zomorodi, S. Blaney, N. **Winick**, M. Bernstein, and M.P. Link, *Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study.* Clin Cancer Res, 2002. **8**(2): p. 413-8.

 56. Scothorn, D.J., N.J. **Winick**, C.F. Timmons, and V.M. Aquino, *Rapidly fatal acute bacterial myocarditis in a nonneutropenic child with acute lymphoblastic leukemia in remission.* J Pediatr Hematol Oncol, 2002. **24**(8): p. 662-5.

 57. Bowers, D.C., L. Gargan, P. Kapur, J.S. Reisch, A.F. Mulne, K.N. Shapiro, R.D. Elterman, N.J. **Winick**, and L.R. Margraf, *Study of the MIB-1 labeling index as a predictor of tumor progression in pilocytic astrocytomas in children and adolescents.* J Clin Oncol, 2003. **21**(15): p. 2968-73.

 58. Kennard BD, Stewart SM, Olvera R, Bawdon RE, Hailin AO, Lewis CP, Winick NJ: Nonadherence in Adolescent Oncology Patients: Preliminary Data on Psychological Risk Factors and Relationships to Outcome. J Clin Psych Med Settings; 2004 March 11(1) 31-39.

 59. Aquino, V.M., S.D. Weitman, N.J. **Winick**, S. Blaney, W.L. Furman, J.L. Kepner, P. Bonate, M. Krailo, W. Qu, and M. Bernstein, *Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: a pediatric oncology group study.* J Clin Oncol, 2004. **22**(8): p. 1413-9.

 60. Bomgaars, L., J.R. Geyer, J. Franklin, G. Dahl, J. Park, N.J. **Winick**, R. Klenke, S.L. Berg, and S.M. Blaney, *Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis.* J Clin Oncol, 2004. **22**(19): p. 3916-21.

 61. Bowers, D.C., V.M. Aquino, P.J. Leavey, R.O. Bash, J.M. Journeycake, G. Tomlinson, A.F. Mulne, H.J. Haynes, and N.J. **Winick**, *Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors.* Pediatr Blood Cancer, 2004. **42**(1): p. 93-8.

 62. Quinn, C.T., J.C. Griener, T. Bottiglieri, E. Arning, and N.J. **Winick**, *Effects of intraventricular methotrexate on folate, adenosine, and homocysteine metabolism in cerebrospinal fluid.* J Pediatr Hematol Oncol, 2004. **26**(6): p. 386-8.

 63. Rollins, N., N. **Winick**, R. Bash, and T. Booth, *Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome.* AJNR Am J Neuroradiol, 2004. **25**(10): p. 1688-95.

 64. Schuetz, E.G., M.V. Relling, S. Kishi, W. Yang, S. Das, P. Chen, E.H. Cook, G.L. Rosner, C.H. Pui, J.G. Blanco, M.J. Edick, M.L. Hancock, N.J. **Winick**, T. Dervieux, M.D. Amylon, R.O. Bash, F.G. Behm, B.M. Camitta, S.C. Raimondi, B.C. Goh, S.C. Lee, L.Z. Wang, L. Fan, J.Y. Guo, J. Lamba, R. Lim, H.L. Lim, A.B. Ong, H.S. Lee, P. Kuehl, J. Zhang, Y. Lin, M. Assem, J. Schuetz, P.B. Watkins, A. Daly, S.A. Wrighton, S.D. Hall, P. Maurel, C. Brimer, K. Yasuda, R. Venkataramanan, S. Strom, K. Thummel, and M.S. Boguski, *PharmGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5.* Pharmacol Rev, 2004. **56**(2): p. 159.

 65. **Winick**, N.J., W.L. Carroll, and S.P. Hunger, *Childhood leukemia--new advances and challenges.* N Engl J Med, 2004. **351**(6): p. 601-3.

 66. Borowitz, M.J., D.J. Pullen, N. **Winick**, P.L. Martin, W.P. Bowman, and B. Camitta, *Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group.* Cytometry B Clin Cytom, 2005. **68**(1): p. 18-24.

 67. Giller, C.A., B.D. Berger, D.A. Pistenmaa, F. Sklar, B. Weprin, K. Shapiro, N. **Winick**, A.F. Mulne, J.L. Delp, J.P. Gilio, K.P. Gall, K.A. Dicke, D. Swift, D. Sacco, K. Harris-Henderson, and D. Bowers, *Robotically guided radiosurgery for children.* Pediatr Blood Cancer, 2005. **45**(3): p. 304-10.

 68. Hunger, S.P., N.J. **Winick**, H.N. Sather, and W.L. Carroll, *Therapy of low-risk subsets of childhood acute lymphoblastic leukemia: when do we say enough?* Pediatr Blood Cancer, 2005. **45**(7): p. 876-80.

 69. Barredo, J.C., M. Devidas, S.J. Lauer, A. Billett, M. Marymont, J. Pullen, B. Camitta, N. **Winick**, W. Carroll, and A.K. Ritchey, *Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study.* J Clin Oncol, 2006. **24**(19): p. 3142-9.

 70. Bowers, D.C., L. Gargan, B.E. Weprin, A.F. Mulne, R.D. Elterman, L. Munoz, C.A. Giller, and N.J. **Winick**, *Impact of site of tumor recurrence upon survival for children with recurrent or progressive medulloblastoma.* J Neurosurg, 2007. **107**(1 Suppl): p. 5-10.

 71. Schultz, K.R., D.J. Pullen, H.N. Sather, J.J. Shuster, M. Devidas, M.J. Borowitz, A.J. Carroll, N.A. Heerema, J.E. Rubnitz, M.L. Loh, E.A. Raetz, N.J. **Winick**, S.P. Hunger, W.L. Carroll, P.S. Gaynon, and B.M. Camitta, *Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).* Blood, 2007. **109**(3): p. 926-35.

 72. Borowitz, M.J., M. Devidas, S.P. Hunger, W.P. Bowman, A.J. Carroll, W.L. Carroll, S. Linda, P.L. Martin, D.J. Pullen, D. Viswanatha, C.L. Willman, N. **Winick**, B.M. Camitta, and G. Children's Oncology, *Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.* Blood, 2008. **111**(12): p. 5477-85.

 73. Davies, S.M., M.J. Borowitz, G.L. Rosner, K. Ritz, M. Devidas, N. **Winick**, P.L. Martin, P. Bowman, J. Elliott, C. Willman, S. Das, E.H. Cook, and M.V. Relling, *Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group.* Blood, 2008. **111**(6): p. 2984-90.

 74. Nguyen, K., M. Devidas, S.C. Cheng, M. La, E.A. Raetz, W.L. Carroll, N.J. **Winick**, S.P. Hunger, P.S. Gaynon, M.L. Loh, and G. Children's Oncology, *Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study.* Leukemia, 2008. **22**(12): p. 2142-50.

 75. Raetz, E.A., M.J. Borowitz, M. Devidas, S.B. Linda, S.P. Hunger, N.J. **Winick**, B.M. Camitta, P.S. Gaynon, and W.L. Carroll, *Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected].* J Clin Oncol, 2008. **26**(24): p. 3971-8.

 76. Slone, T.L., R. Rai, N. Ahmad, and N.J. **Winick**, *Risk factors for readmission after initial diagnosis in children with acute lymphoblastic leukemia.* Pediatr Blood Cancer, 2008. **51**(3): p. 375-9.

 75. Schultz, K.R., W.P. Bowman, A. Aledo, W.B. Slayton, H. Sather, M. Devidas, C. Wang, S.M. Davies, P.S. Gaynon, M. Trigg, R. Rutledge, L. Burden, D. Jorstad, A. Carroll, N.A. Heerema, N. **Winick**, M.J. Borowitz, S.P. Hunger, W.L. Carroll, and B. Camitta, *Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.* J Clin Oncol, 2009. **27**(31): p. 5175-81.

 78. **Winick**, N., *Is immunization necessary after therapy for acute lymphoblastic leukemia (ALL) has been completed?* Pediatr Blood Cancer, 2009. **53**(6): p. 922-3.

 79. Berg, S.L., N. **Winick**, A.M. Ingle, P.C. Adamson, and S.M. Blaney, *Reasons for participation in optional pharmacokinetic studies in children with cancer: a Children's Oncology Group phase 1 consortium study.* Pediatr Blood Cancer, 2010. **55**(1): p. 119-22.

 80. Horton, T.M., R. Sposto, P. Brown, C.P. Reynolds, S.P. Hunger, N.J. **Winick**, E.A. Raetz, W.L. Carroll, R.J. Arceci, M.J. Borowitz, P.S. Gaynon, L. Gore, S. Jeha, B.J. Maurer, S.E. Siegel, A. Biondi, P.R. Kearns, A. Narendran, L.B. Silverman, M.A. Smith, C.M. Zwaan, J.A. Whitlock, and A. Conference, *Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference.* Pediatr Blood Cancer, 2010. **54**(7): p. 872-8.

 81. Maloney, K.W., W.L. Carroll, A.J. Carroll, M. Devidas, M.J. Borowitz, P.L. Martin, J. Pullen, J.A. Whitlock, C.L. Willman, N.J. **Winick**, B.M. Camitta, and S.P. Hunger, *Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group.* Blood, 2010. **116**(7): p. 1045-50.

 82. Salzer, W.L., M. Devidas, W.L. Carroll, N. **Winick**, J. Pullen, S.P. Hunger, and B.A. Camitta, *Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group.* Leukemia, 2010. **24**(2): p. 355-70.

 83. Tirado, C.A., W. Chen, L.J. Huang, C. Laborde, M.C. Hiemenz, F. Valdez, K. Ho, N. **Winick**, Z. Lou, and P. Koduru, *Novel JAK2 rearrangement resulting from a t(9;22)(p24;q11.2) in B-acute lymphoblastic leukemia.* Leuk Res, 2010. **34**(12): p. 1674-6.

 84. Beuten, J., J.A. Gelfond, D. Piwkham, B.H. Pollock, N.J. **Winick**, A.B. Collier, 3rd, and G.E. Tomlinson, *Candidate gene association analysis of acute lymphoblastic leukemia identifies new susceptibility locus at 11p15 (LMO1).* Carcinogenesis, 2011. **32**(9): p. 1349-53.

 85. Bowman, W.P., E.L. Larsen, M. Devidas, S.B. Linda, L. Blach, A.J. Carroll, W.L. Carroll, D.J. Pullen, J. Shuster, C.L. Willman, N. **Winick**, B.M. Camitta, S.P. Hunger, and M.J. Borowitz, *Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.* Pediatr Blood Cancer, 2011. **57**(4): p. 569-77.

 86. Hiemenz, M.C., W. Chen, N. **Winick**, R. Garcia, and C.A. Tirado, *Coexistence of t(12;21)(p13;q22)/ETV6-RUNX1 and 11q23/MLL Rearrangement in B Acute Lymphoblastic Leukemia: A Case Report and Review of the Literature.* J Assoc Genet Technol, 2011. **37**(4): p. 213-5.

 87. Matloub, Y., B.C. Bostrom, S.P. Hunger, L.C. Stork, A. Angiolillo, H. Sather, M. La, J.M. Gastier-Foster, N.A. Heerema, S. Sailer, P.J. Buckley, B. Thomson, C. Cole, J.B. Nachman, G. Reaman, N. **Winick**, W.L. Carroll, M. Devidas, and P.S. Gaynon, *Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.* Blood, 2011. **118**(2): p. 243-51.

 88. Piwkham, D., J.A. Gelfond, B. Rerkamnuaychoke, S. Pakakasama, V.I. Rebel, B.H. Pollock, N.J. **Winick**, A.B. Collier, 3rd, G.E. Tomlinson, and J. Beuten, *Multilocus association of genetic variants in MLL, CREBBP, EP300, and TOP2A with childhood acute lymphoblastic leukemia in Hispanics from Texas.* Cancer Epidemiol Biomarkers Prev, 2011. **20**(6): p. 1204-12.

 89. Sung, L., R. Yanofsky, R.J. Klaassen, D. Dix, S. Pritchard, N. **Winick**, S. Alexander, and A. Klassen, *Quality of life during active treatment for pediatric acute lymphoblastic leukemia.* Int J Cancer, 2011. **128**(5): p. 1213-20.

 90. Swinney, R.M., J. Beuten, A.B. Collier, 3rd, T.T. Chen, N.J. **Winick**, B.H. Pollock, and G.E. Tomlinson, *Polymorphisms in CYP1A1 and ethnic-specific susceptibility to acute lymphoblastic leukemia in children.* Cancer Epidemiol Biomarkers Prev, 2011. **20**(7): p. 1537-42.

 91. **Winick**, N., *Neurocognitive outcome in survivors of pediatric cancer.* Curr Opin Pediatr, 2011. **23**(1): p. 27-33.

 92. Yang, J.J., C. Cheng, M. Devidas, X. Cao, Y. Fan, D. Campana, W. Yang, G. Neale, N.J. Cox, P. Scheet, M.J. Borowitz, N.J. **Winick**, P.L. Martin, C.L. Willman, W.P. Bowman, B.M. Camitta, A. Carroll, G.H. Reaman, W.L. Carroll, M. Loh, S.P. Hunger, C.H. Pui, W.E. Evans, and M.V. Relling, *Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia.* Nat Genet, 2011. **43**(3): p. 237-41.

 93. Aquino, V.M., C. Cost, A. Gomez, D.C. Bowers, O. Ramilo, N. Ahmad, N. **Winick**, and P.J. Leavey, *Predictive value of interleukin-5 and monocyte chemotactic protein-1 for bacteremia in children with febrile neutropenia.* J Pediatr Hematol Oncol, 2012. **34**(6): p. e241-5.

 94. Blanco, E., J. Beyene, A.M. Maloney, R. Almeida, M.C. Ethier, N. **Winick**, S. Alexander, and L. Sung, *Non-relapse mortality in pediatric acute lymphoblastic leukemia: a systematic review and meta-analysis.* Leuk Lymphoma, 2012. **53**(5): p. 878-85.

 95. Chang, B.H., S.G. Willis, L. Stork, S.P. Hunger, W.L. Carroll, B.M. Camitta, N.J. **Winick**, B.J. Druker, and K.R. Schultz, *Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study.* Br J Haematol, 2012. **157**(4): p. 507-10.

 96. Chen, I.M., R.C. Harvey, C.G. Mullighan, J. Gastier-Foster, W. Wharton, H. Kang, M.J. Borowitz, B.M. Camitta, A.J. Carroll, M. Devidas, D.J. Pullen, D. Payne-Turner, S.K. Tasian, S. Reshmi, C.E. Cottrell, G.H. Reaman, W.P. Bowman, W.L. Carroll, M.L. Loh, N.J. **Winick**, S.P. Hunger, and C.L. Willman, *Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.* Blood, 2012. **119**(15): p. 3512-22.

 97. Dunsmore, K.P., M. Devidas, S.B. Linda, M.J. Borowitz, N. **Winick**, S.P. Hunger, W.L. Carroll, and B.M. Camitta, *Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.* J Clin Oncol, 2012. **30**(22): p. 2753-9.

 98. Hunger, S.P., X. Lu, M. Devidas, B.M. Camitta, P.S. Gaynon, N.J. **Winick**, G.H. Reaman, and W.L. Carroll, *Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.* J Clin Oncol, 2012. **30**(14): p. 1663-9.

 99. Kang, H., C.S. Wilson, R.C. Harvey, I.M. Chen, M.H. Murphy, S.R. Atlas, E.J. Bedrick, M. Devidas, A.J. Carroll, B.W. Robinson, R.W. Stam, M.G. Valsecchi, R. Pieters, N.A. Heerema, J.M. Hilden, C.A. Felix, G.H. Reaman, B. Camitta, N. **Winick**, W.L. Carroll, Z.E. Dreyer, S.P. Hunger, and C.L. Willman, *Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study.* Blood, 2012. **119**(8): p. 1872-81.

100. McCavit, T.L. and N. **Winick**, *Time-to-antibiotic administration as a quality of care measure in children with febrile neutropenia: a survey of pediatric oncology centers.* Pediatr Blood Cancer, 2012. **58**(2): p. 303-5.

101. Salzer, W.L., T.L. Jones, M. Devidas, J.M. Hilden, N. **Winick**, S. Hunger, W.L. Carroll, B. Camitta, and Z.E. Dreyer, *Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407.* Pediatr Blood Cancer, 2012. **59**(5): p. 834-9.

102. Salzer, W.L., N.J. **Winick**, P. Wacker, X. Lu, M. Devidas, J.J. Shuster, D.H. Mahoney, S.J. Lauer, and B.M. Camitta, *Plasma methotrexate, red blood cell methotrexate, and red blood cell folate values and outcome in children with precursor B-acute lymphoblastic leukemia: a report from the Children's Oncology Group.* J Pediatr Hematol Oncol, 2012. **34**(1): p. e1-7.

103. Xu, H., C. Cheng, M. Devidas, D. Pei, Y. Fan, W. Yang, G. Neale, P. Scheet, E.G. Burchard, D.G. Torgerson, C. Eng, M. Dean, F. Antillon, N.J. **Winick**, P.L. Martin, C.L. Willman, B.M. Camitta, G.H. Reaman, W.L. Carroll, M. Loh, W.E. Evans, C.H. Pui, S.P. Hunger, M.V. Relling, and J.J. Yang, *ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia.* J Clin Oncol, 2012. **30**(7): p.751-7.

104. Yang, J.J., C. Cheng, M. Devidas, X. Cao, D. Campana, W. Yang, Y. Fan, G. Neale, N. Cox, P. Scheet, M.J. Borowitz, N.J. **Winick**, P.L. Martin, W.P. Bowman, B. Camitta, G.H. Reaman, W.L. Carroll, C.L. Willman, S.P. Hunger, W.E. Evans, C.H. Pui, M. Loh, and M.V. Relling, *Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia.* Blood, 2012. **120**(20): p. 4197-204.

105. Hunger, S.P., M.L. Loh, J.A. Whitlock, N.J. **Winick**, W.L. Carroll, M. Devidas, E.A. Raetz, and C.O.G.Acute Lymphoblastic Leukemia Committee on behalf of the, *Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.* Pediatr Blood Cancer, 2013. **60**(6): p. 957-63. PMID: 23255467 [PubMed - indexed for MEDLINE]

106. Fletcher, M., H. Hodgkiss, S. Zhang, R. Browning, C. Hadden, T. Hoffman, N. **Winick**, and T.L. McCavit, *Prompt administration of antibiotics is associated with improved outcomes in febrile neutropenia in children with cancer.* Pediatr Blood Cancer, 2013.

107. Loh, M.L., J. Zhang, R.C. Harvey, K. Roberts, D. Payne-Turner, H. Kang, G. Wu, X. Chen, J. Becksfort, M. Edmonson, K.H. Buetow, W.L. Carroll, I.M. Chen, B. Wood, M.J. Borowitz, M. Devidas, D.S. Gerhard, P. Bowman, E. Larsen, N. **Winick**, E. Raetz, M. Smith, J.R. Downing, C.L. Willman, C.G. Mullighan, and S.P. Hunger, *Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project.* Blood, 2013. **121**(3): p. 485-8.

108. Ramsey, L.B., J.C. Panetta, C. Smith, W. Yang, Y. Fan, N.J. **Winick**, P.L. Martin, C. Cheng, M. Devidas, C.H. Pui, W.E. Evans, S.P. Hunger, M. Loh, and M.V. Relling, *Genome-wide study of methotrexate clearance replicates SLCO1B1.* Blood, 2013. **121**(6): p. 898-904.

109. Xu, H., W. Yang, V. Perez-Andreu, M. Devidas, Y. Fan, C. Cheng, D. Pei, P. Scheet, E.G. Burchard, C. Eng, S. Huntsman, D.G. Torgerson, M. Dean, N.J. **Winick**, P.L. Martin, B.M. Camitta, W.P. Bowman, C.L. Willman, W.L. Carroll, C.G. Mullighan, D. Bhojwani, S.P. Hunger, C.H. Pui, W.E. Evans, M.V. Relling, M.L. Loh, and J.J. Yang, *Novel Susceptibility Variants at 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethnically Diverse Populations.* J Natl Cancer Inst, 2013. **105**(10): p.733-42. PMID: 23512250 [PubMed - indexed for MEDLINE]

110. Salzer WL, Asselin B, Supko JG, Devidas M, Kaiser NA, Plourde P, **Winick** NJ, Reaman GH, Raetz E, Carroll WL, Hunger SP. *Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group*. Blood, 2013. **122**(4): p. 507-14. PMID: 23741010

111. Thienprayoon R, Lee SC, Leonard D, **Winick** N. *Racial and ethnic differences in hospice enrollment among children with cancer.* Pediatr Blood Cancer, 2013. **60**(10):1662-6. PMID:23733549

112. Schmiegelow K, Levinsen MF, Attarbaschi A, Baruchel A, Devidas M, Escherich G, Gibson B, Heydrich C, Horibe K, Ishida Y, Liang DC, Locatelli F, Michel G, Pieters R, Piette C, Pui CH, Raimondi S, Silverman L, Stanulla M, Stark B, **Winick** N, Valsecchi MG. *Second Malignant Neoplasms After Treatment of Childhood Acute Lymphoblastic Leukemia.* J Clin Oncol, 2013. **31**(l9): p. 2469-76. PMID: 23690411

113. Hunger SP, Loh ML, Whitlock JA, **Winick** NJ, Carroll WL, Devidas M, Raetz EA; *COG Acute Lymphoblastic Leukemia Committee. Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.* Pediatr Blood Cancer,2013. **60**(6): p. 957-63. PMID: 23255467 [PubMed - indexed for MEDLINE]

114. Chen KS, Bach A, Shoup A, **Winick** NJ**.** [*Hearing loss and vestibular dysfunction among children with cancer after receiving aminoglycosides.*](http://www.ncbi.nlm.nih.gov/pubmed/23788258) Pediatr Blood Cancer, 2013. **60**(11): p. 1772-7. PMID: 23788258 [PubMed - indexed for MEDLINE]

115. Heerema NA, Carroll AJ, Devidas M, Loh ML, Borowitz MJ, Gastier-Foster JM, Larsen EC, Mattano LA Jr, Maloney KW, Willman CL, Wood BL, **Winick** NJ, Carroll WL, Hunger SP, Raetz EA. [*Intrachromosomal Amplification of Chromosome 21 Is Associated With Inferior Outcomes in Children With Acute Lymphoblastic Leukemia Treated in Contemporary Standard-Risk Children's Oncology Group Studies: A Report From the Children's Oncology Group.*](http://www.ncbi.nlm.nih.gov/pubmed/23940221)J Clin Oncol, 2013. **31**(27): p. 3397-3402. PMID: 23940221 [PubMed - in process]

116. Perez-Andreu V, Roberts KG, Harvey RC, Yang W, Cheng C, Pei D, Xu H, Gastier-Foster J, E S, Lim JY, Chen IM, Fan Y, Devidas M, Borowitz MJ, Smith C, Neale G, Burchard EG, Torgerson DG, Klussmann FA, Villagran CR, **Winick** NJ, Camitta BM, Raetz E, Wood B, Yue F, Carroll WL, Larsen E, Bowman WP, Loh ML, Dean M, Bhojwani D, Pui CH, Evans WE, Relling MV, Hunger SP, Willman CL, Mullighan CG, Yang JJ. [*Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse.*](http://www.ncbi.nlm.nih.gov/pubmed/24141364) Nat Genet, 2013. **45**(12): p. 1494-8. PMID: 24141364 [PubMed - in process]

117. Pokala HR, Leonard D, Cox J, Metcalf P, McClay J, Siegel J, **Winick** N. Association of

 hospital construction with the development of healthcare associated environmental mold

 infections (HAEMI) in pediatric patients with leukemia. Pediatr Blood Cancer, 2014.

 **61**(2): p. 276-80. PMID: 23970381 [PubMed - in process]

118. Schultz KR, Carroll A, Heerema NA, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, Zheng HW, Davies SM, Gaynon PS, Trigg M, Rutledge R, Jorstad D, **Winick** N, Borowitz MJ, Hunger SP, Carroll WL, Camitta B. [*Long term follow-up of imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia: children's oncology group study AALL0031.*](http://www.ncbi.nlm.nih.gov/pubmed/24441288)Leukemia, 2014 Jan 20. doi: 10.1038/ leu.2014.30. [Epub ahead of print] PMID: 24441288. P1467-1471 [PubMed - as supplied by publisher]

119. Myers RM, Balsamo L, Lu X, Devidas M, Hunger SP, Carroll WL, **Winick** NJ, Maloney

 KW, Kadan-Lottick NS. *A prospective study of anxiety, depression, and behavioral*

 *changes in the first year after a diagnosis of childhood acute lymphoblastic leukemia: A*

 *report from the Children's Oncology Group.* Cancer, 2014 Jan 28. doi:

 10.1002/cncr.28578. [Epub ahead of print] PMID: 24473774 [PubMed - as supplied by

 publisher]

120. [Wang X](http://www.ncbi.nlm.nih.gov/pubmed?term=Wang%20X%5BAuthor%5D&cauthor=true&cauthor_uid=24470002), [Liu W](http://www.ncbi.nlm.nih.gov/pubmed?term=Liu%20W%5BAuthor%5D&cauthor=true&cauthor_uid=24470002), [Sun CL](http://www.ncbi.nlm.nih.gov/pubmed?term=Sun%20CL%5BAuthor%5D&cauthor=true&cauthor_uid=24470002), [Armenian SH](http://www.ncbi.nlm.nih.gov/pubmed?term=Armenian%20SH%5BAuthor%5D&cauthor=true&cauthor_uid=24470002), [Hakonarson H](http://www.ncbi.nlm.nih.gov/pubmed?term=Hakonarson%20H%5BAuthor%5D&cauthor=true&cauthor_uid=24470002), [Hageman L](http://www.ncbi.nlm.nih.gov/pubmed?term=Hageman%20L%5BAuthor%5D&cauthor=true&cauthor_uid=24470002), [Ding Y](http://www.ncbi.nlm.nih.gov/pubmed?term=Ding%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=24470002), [Landier W](http://www.ncbi.nlm.nih.gov/pubmed?term=Landier%20W%5BAuthor%5D&cauthor=true&cauthor_uid=24470002), [Blanco JG](http://www.ncbi.nlm.nih.gov/pubmed?term=Blanco%20JG%5BAuthor%5D&cauthor=true&cauthor_uid=24470002), [Chen L](http://www.ncbi.nlm.nih.gov/pubmed?term=Chen%20L%5BAuthor%5D&cauthor=true&cauthor_uid=24470002), [Quiñones A](http://www.ncbi.nlm.nih.gov/pubmed?term=Qui%C3%B1ones%20A%5BAuthor%5D&cauthor=true&cauthor_uid=24470002), [Ferguson D](http://www.ncbi.nlm.nih.gov/pubmed?term=Ferguson%20D%5BAuthor%5D&cauthor=true&cauthor_uid=24470002), [**Winick** N](http://www.ncbi.nlm.nih.gov/pubmed?term=Winick%20N%5BAuthor%5D&cauthor=true&cauthor_uid=24470002), [Ginsberg JP](http://www.ncbi.nlm.nih.gov/pubmed?term=Ginsberg%20JP%5BAuthor%5D&cauthor=true&cauthor_uid=24470002), [Keller F](http://www.ncbi.nlm.nih.gov/pubmed?term=Keller%20F%5BAuthor%5D&cauthor=true&cauthor_uid=24470002), [Neglia JP](http://www.ncbi.nlm.nih.gov/pubmed?term=Neglia%20JP%5BAuthor%5D&cauthor=true&cauthor_uid=24470002), [Desai S](http://www.ncbi.nlm.nih.gov/pubmed?term=Desai%20S%5BAuthor%5D&cauthor=true&cauthor_uid=24470002), [Sklar CA](http://www.ncbi.nlm.nih.gov/pubmed?term=Sklar%20CA%5BAuthor%5D&cauthor=true&cauthor_uid=24470002), [Castellino SM](http://www.ncbi.nlm.nih.gov/pubmed?term=Castellino%20SM%5BAuthor%5D&cauthor=true&cauthor_uid=24470002), [Cherrick I](http://www.ncbi.nlm.nih.gov/pubmed?term=Cherrick%20I%5BAuthor%5D&cauthor=true&cauthor_uid=24470002), [Dreyer ZE](http://www.ncbi.nlm.nih.gov/pubmed?term=Dreyer%20ZE%5BAuthor%5D&cauthor=true&cauthor_uid=24470002), [Hudson MM](http://www.ncbi.nlm.nih.gov/pubmed?term=Hudson%20MM%5BAuthor%5D&cauthor=true&cauthor_uid=24470002), [Robison LL](http://www.ncbi.nlm.nih.gov/pubmed?term=Robison%20LL%5BAuthor%5D&cauthor=true&cauthor_uid=24470002), [Yasui Y](http://www.ncbi.nlm.nih.gov/pubmed?term=Yasui%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=24470002), [Relling MV](http://www.ncbi.nlm.nih.gov/pubmed?term=Relling%20MV%5BAuthor%5D&cauthor=true&cauthor_uid=24470002), [Bhatia S](http://www.ncbi.nlm.nih.gov/pubmed?term=Bhatia%20S%5BAuthor%5D&cauthor=true&cauthor_uid=24470002). *Hyaluronan Synthase 3 Variant and Anthracycline-Related Cardiomyopathy: A Report From the Children's Oncology Group.* J Clin Oncol, 2014 Jan 27. [Epub ahead of print] PMID: 24470002 [PubMed - as supplied by publisher]

121. Schultz KR, Devidas M, Bowman WP, Aledo A, Slayton WB, Sather H, Zheng HW,

 Davies SM, Gaynon PS, Trigg M, Rutledge R, Jorstad D, Carroll AJ, Heerema N,

 **Winick** N, Borowitz MJ,Hunger SP, Carroll WL, Camitta B. *Philadelphia chromosome-*

 *negative very high-risk acute lymphoblastic leukemia in children and adolescents: results*

 *from Children's Oncology Group Study AALL0031.* Leukemia, 2014 Jan 17. doi: 10.1038/leu.2014.29. [Epub ahead of print] PMID: 24434862 [PubMed - as supplied by publisher]

122. Schultz KR, Devidas M, Bowman WP, Aledo A, Slayton WB, Sather H, Zheng HW, Davies SM, Gaynon PS, Trigg M, Rutledge R, Jorstad D, Carroll AJ, Heerema N, **Winick** N**,** Borowitz MJ, Hunger SP, Carroll WL, Camitta B; Children’s Oncology Group.  *Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children's Oncology Group Study AALL0031.* Leukemia. 2014 Apr;28(4):964-7. doi: 10.1038/leu. 2014.29. Epub 2014 Jan 17. No abstract available. PMID: 24434862 [PubMed - indexed for MEDLINE]

123. Tower RL, Jones TL, Camitta BM, Asselin BL, Bell BA, Chauvenet A, Devidas M, Halperin EC, Pullen J, Shuster JJ, **Winick** N, Kurtzberg J. Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group. J Pediatr Hematol Oncol. 2014 Jul;36(5):353-61. doi: 10.1097/MPH. 0000000000000131. PMID: 24608079 [PubMed - indexed for MEDLINE]

124. Fernandez CA, Smith C, Yang W, Daté M, Bashford D, Larsen E, Bowman WP, Liu C, Ramsey LB, Chang T, Turner V, Loh ML, Raetz EA, **Winick** NJ, Hunger SP, Carroll WL, Onengut- Gumuscu S, Chen WM, Concannon P, Rich SS, Scheet P, Jeha S, Pui CH, Evans WE, Devidas M, Relling MV. *HLA-DRB1\*07:01 is associated with a higher risk of asparaginase allergies.* Blood. 2014 Aug 21;124(8):1266-76. doi: 10.1182/blood-2014-03-563742. Epub 2014 Jun 26. PMID: 24970932 [PubMed - indexed for MEDLINE]

125. Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, McCastlain K, Ding L, Lu C, Song G, Ma J, Becksfort J, Rusch M, Chen SC, Easton J, Cheng J, Boggs K, Santiago-Morales N, Iacobucci I, Fulton RS, Wen J, Valentine M, Cheng C, Paugh SW, Devidas M, Chen IM, Reshmi S, Smith A, Hedlund E, Gupta P, Nagahawatte P, Wu G, Chen X, Yergeau D, Vadodaria B, Mulder H, **Winick** NJ, Larsen EC, Carroll WL, Heerema NA, Carroll AJ, Grayson G, Tasian SK, Moore AS, Keller F, Frei-Jones M, Whitlock JA, Raetz EA, White DL, Hughes TP, Guidry Auvil JM, Smith MA, Marcucci G, Bloomfield CD, Mrózek K, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Pui CH, Jeha S, Relling MV, Evans WE, Gerhard DS, Gastier-Foster JM, Mardis E, Wilson RK, Loh ML, Downing JR, Hunger SP, Willman CL, Zhang J, Mullighan CG. *Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.* N Engl J Med. 2014 Sep 11;371(11):1005-15. doi: 10.1056/NEJMoa1403088. PMID: 25207766 [PubMed - indexed for MEDLINE]

126. Salzer WL, Jones TL, Devidas M, Dreyer ZE, Gore L, **Winick** NJ, Sung L, Raetz E, Loh ML, Wang CY, De Lorenzo P, Valsecchi MG, Pieters R, Carroll WL, Hunger SP, Hilden JM, Brown P. *Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: A report from the children's oncology group.* Pediatr Blood Cancer. 2014 Nov 18. doi: 10.1002/pbc.25311. P.414-418 [Epub ahead of print]

127. Dreyer ZE, Hilden JM, Jones TL, Devidas M, **Winick** NJ**,** Willman CL, Harvey RC, Chen IM, Behm FG, Pullen J, Wood BL, Carroll AJ, Heerema NA, Felix CA, Robinson B, Reaman GH, Salzer WL, Hunger SP, Carroll WL, Camitta BM. *Intensified chemotherapy without SCT in infant ALL: Results from COG P9407 (Cohort 3).* Pediatr Blood Cancer. 2014 Nov 14. doi:10.1002/pbc.25322. [Epub ahead of print] PMID: 25399948. P.419-426 [PubMed - as supplied by publisher

128. Lau S, Lu X, Balsamo L, Devidas M, **Winick** N, Hunger SP, Carroll W, Stork L, Maloney K, Kadan-Lottick N. Family life events in the first year of acute lymphoblastic leukemia therapy: a children's oncology group report. Pediatr Blood Cancer. 2014 Dec;61(12):2277-84. doi: 10.1002/pbc.25195. Epub 2014 Aug 30. PMID: 25175168 [PubMed - in process]

129. Angiolillo AL, Schore RJ, Devidas M, Borowitz MJ, Carroll AJ, Gastier-Foster JM, Heerema NA, Keilani T, Lane AR, Loh ML, Reaman GH, Adamson PC, Wood B, Wood C, Zheng HW, Raetz EA, **Winick** NJ, Carroll WL, Hunger SP. *Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.* J Clin Oncol. 2014 Dec 1;32(34):3874-82. doi: 10.1200/JCO.2014.55.5763. Epub 2014 Oct 27. PMID: 25348002 [PubMed - indexed for MEDLINE]

130. Leger K, Slone T, Lemler M, Leonard D, Cochran C, Bowman WP, Bashore L, **Winick** N. *Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy.* Pediatr Blood Cancer. 2015 Jan;62(1):123-7. doi: 10.1002/pbc.25206. Epub 2014 Aug 30. PMID: 25176022 [PubMed - in process]

131. Diouf B, Crews KR, Lew G, Pei D, Cheng C, Bao J, Zheng JJ, Yang W, Fan Y, Wheeler HE, Wing C, Delaney SM, Komatsu M, Paugh SW, McCorkle JR, Lu X, **Winick** NJ, Carroll WL, Loh ML, Hunger SP, Devidas M, Pui CH, Dolan ME, Relling MV, Evans WE. *Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.* JAMA. 2015 Feb 24;313 (8):815-23. doi: 10.1001/jama.2015.0894. PMID: 25710658 [PubMed - indexed for MEDLINE]

132. Salzer WL, Jones TL, Devidas M, Dreyer ZE, Gore L, **Winick** NJ, Sung L, Raetz E, Loh ML, Wang CY, De Lorenzo P, Valsecchi MG, Pieters R, Carroll WL, Hunger SP, Hilden JM, Brown P. *Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group.* Pediatr Blood Cancer. 2015 Mar;62(3):414-8. doi: 10.1002/pbc. 25311. Epub 2014 Nov 18. PMID: 25407157 [PubMed - indexed for MEDLINE]

133. Dreyer ZE, Hilden JM, Jones TL, Devidas M, **Winick** NJ, Willman CL, Harvey RC, Chen IM, Behm FG, Pullen J, Wood BL, Carroll AJ, Heerema NA, Felix CA, Robinson B, Reaman GH, Salzer WL, Hunger SP, Carroll WL, Camitta BM. *Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3).* Pediatr Blood Cancer. 2015 Mar;62(3):419-26. doi: 10.1002/pbc.25322. Epub 2014 Nov 14. PMID: 25399948 [PubMed - indexed for MEDLINE]

134. Borowitz MJ, Wood BL, Devidas M, Loh ML, Raetz EA, Salzer WL, Nachman JB, Carroll AJ, Heerema NA, Gastier-Foster JM, Willman CL, Dai Y, **Winick** NJ, Hunger SP, Carroll WL, Larsen E. *Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.* Blood. 2015 Jun 29. pii: blood-2015-03-633685. [Epub ahead of print] PMID: 26124497. p.964-971 [PubMed - as supplied by publisher]

135. Xu H, Zhang H, Yang W, Yadav R, Morrison AC, Qian M, Devidas M, Liu Y, Perez-Andreu V, Zhao X, Gastier-Foster JM, Lupo PJ, Neale G, Raetz E, Larsen E, Bowman WP, Carroll WL, **Winick** N, Williams R, Hansen T, Holm JC, Mardis E, Fulton R, Pui CH, Zhang J, Mullighan CG, Evans WE, Hunger SP, Gupta R, Schmiegelow K, Loh ML, Relling MV, Yang JJ. *Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children.* Nat Commun. 2015 Jun 24;6:7553. doi: 10.1038/ncomms8553. PMID: 26104880. p.1-7 [PubMed - in process]

136. Thienprayoon R, Campbell R, **Winick** N. *Attitudes and Practices in the Bereavement Care Offered by Children's Hospitals: A Survey of the Pediatric Chaplains Network.* Omega (Westport). Jul 2015;71(1):48-59. PMID: 26152026 [PubMed - in process]

137. Thienprayoon R, Lee SC, Leonard D, **Winick** N. *Hospice Care for Children With Cancer: Where Do These Children Die?* J Pediatr Hematol Oncol. 2015 Jul;37(5):373-7. doi: 10.1097/MPH.0000000000000331. PMID: 26090871 [PubMed - in process]

138. Fernandez CA, Smith C, Yang W, Mullighan CG, Qu C, Larsen E, Bowman WP, Liu C, Ramsey LB, Chang T, Karol SE, Loh ML, Raetz EA, **Winick** NJ, Hunger SP, Carroll WL, Jeha S, Pui CH, Evans WE, Devidas M, Relling MV. *Genome-wide analysis links NFATC2 with asparaginase hypersensitivity.* Blood. 2015 Jul 2;126(1):69-75. doi: 10.1182/blood-2015-02-628800. Epub 2015 May 18. PMID: 25987655 [PubMed - in process]

139. Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, **Winick** NJ, Carroll WL, Hunger SP. *Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434.* Pediatr Blood Cancer. 2015 Jul;62(7):1176-83. doi: 10.1002/pbc. 25470. Epub 2015 Mar 8. PMID: 25755211 [PubMed - in process]

140. Mitchell HR, Lu X, Myers RM, Sung L, Balsamo LM, Carroll WL, Raetz E, Loh ML,

 Mattano LA, Winick NJ, Devidas M, Hunger SP, Maloney K, Kadan-Lottick NS.  *Prospective, longitudinal assessment of quality of life in children from diagnosis to three*

 *months off treatment for standard risk (SR) acute lymphoblastic leukemia (ALL): Results*

 *of children's oncology group study AALL0331.* Int J Cancer. 2015 Aug 1. doi:10.1002/

ijc.29708. [Epub ahead of print] PMID: 26235006. p.332-339[PubMed - as supplied by publisher]

141. Karol SE, Yang W, Van Driest SL, Chang TY, Kaste S, Bowton E, Basford M,

Bastarache L, Roden DM, Denny JC, Larsen E, **Winick** N, Carroll WL, Cheng C, Pei D,

Fernandez CA, Liu C, Smith C, Loh ML, Raetz EA, Hunger SP, Scheet P, Jeha S, Pui

CH, Evans WE, Devidas M, Mattano LA Jr, Relling MV. *Genetics of glucocorticoid-*

*associated osteonecrosis in children with acute lymphoblastic leukemia*. Blood. 2015 Oct

8;126(15):1770-6. doi: 10.1182/blood-2015-05-643601. PMID: 26265699 [PubMed –

indexed for MEDLINE]

142. Moriyama T, Metzger ML, Wu G, Nishii R, Qian M, Devidas M, Yang W, Cheng C, Cao

 X, Quinn E, Raimondi S, Gastier-Foster JM, Raetz E, Larsen E, Martin PL, Bowman

 WP, **Winick** N, Komada Y, Wang S, Edmonson M, Xu H, Mardis E, Fulton R, Pui CH,

 Mullighan C, Evans WE, Zhang J, Hunger SP, Relling MV, Nichols KE, Loh ML, Yang

 JJ. *Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic*

 *leukaemia: a systematic genetic study.* Lancet Oncol. 2015 Dec;16(16):1659-66. doi:

 10.1016/S1470-2045(15)00369-1. PMID: 26522332 [PubMed - indexed for MEDLINE]

143. Thienprayoon R, Marks E, Funes M, Martinez-Puente LM, **Winick** N, Lee SC.

*Perceptions of the Pediatric Hospice Experience among English- and Spanish-Speaking*

*Families.* J Palliat Med. 2016 Jan;19(1):30-41. doi: 10.1089/jpm.2015.0137. PMID:

26618809 [PubMed - indexed for MEDLINE]

144. Matloub Y, Stork L, Asselin B, Hunger SP, Borowitz M, Jones T, Bostrom B, Gastier-

 Foster JM, Heerema NA, Carroll A, **Winick** N, Carroll WL, Camitta B, Devidas M,

 Gaynon PS. *Outcome of Children with Standard-Risk T-Lineage Acute Lymphoblastic*

 *Leukemia--Comparison among Different Treatment Strategies.* Pediatr Blood Cancer.

2016 Feb;63(2):255-61. doi: 10.1002/pbc.25793. PMID: 26485054 [PubMed - indexed

for MEDLINE]

145. Wang X, Sun CL, Quiñones-Lombraña A, Singh P, Landier W, Hageman L, Mather M, Rotter JI, Taylor KD, Chen YD, Armenian SH, **Winick** N, Ginsberg JP, Neglia JP, Oeffinger KC, Castellino SM, Dreyer ZE, Hudson MM, Robison LL, Blanco JG, Bhatia S. *CELF4 Variant and Anthracycline-Related Cardiomyopathy: A Children's Oncology Group Genome-Wide Association Study.* J Clin Oncol. 2016Mar 10;34(8):863-70. Doi: 10.1200/JCO.201.63.4550. PMID: 26811534 [PubMed – indexed for MEDLINE]

146. Dupuis LL, Lu X, Mitchell HR, Sung L, Devidas M, Mattano LA Jr, Carroll WL, **Winick** N, Hunger SP, Maloney KW, Kadan-Lottick NS. [*Anxiety, pain, and nausea during the treatment of standard-risk childhood acute lymphoblastic leukemia: A prospective, longitudinal study from the Children's Oncology Group.*](http://www.ncbi.nlm.nih.gov/pubmed/26773735) Cancer. 2016 Apr 1;122(7):1116-25. doi: 10.1002/cncr.29876. PMID: 26773735 [PubMed - indexed for MEDLINE]

147. Kunin-Batson AS, Lu X, Balsamo L, Graber K, Devidas M, Hunger SP, Carroll WL, **Winick** NJ, Mattano LA Jr, Maloney KW, Kadan-Lottick NS.  *Prevalence and predictors of anxiety and depression after completion of chemotherapy for childhood acute lymphoblastic leukemia: A prospective longitudinal study.* Cancer. 2016 May 15;122(10):1608-17. doi: 10.1002/cncr.29946. PMID: 27028090 [PubMed - in process]

148. Liu C, Yang W, Devidas M, Cheng C, Pei D, Smith C, Carroll WL, Raetz EA, Bowman WP, Larsen EC, Maloney KW, Martin PL, Mattano LA Jr, **Winick** NJ, Mardis ER, Fulton RS, Bhojwani D, Howard SC, Jeha S, Pui CH, Hunger SP, Evans WE, Loh ML, Relling MV. *Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia*. J Clin Oncol. 2016 Jun 20;34(18):2133-40. doi: 10.1200/JCO.2015.64.5812. PMID: 27114598 [PubMed - in process]

149. Larsen EC, Devidas M, Chen S, Salzer WL, Raetz EA, Loh ML, Mattano LA Jr, Cole C, Eicher A, Haugan M, Sorenson M, Heerema NA, Carroll AA, Gastier-Foster JM, Borowitz MJ, Wood BL, Willman CL, **Winick** NJ, Hunger SP, Carroll WL. *Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232.* J Clin Oncol. 2016 Jul 10;34(20):2380-8. doi: 10.1200/JCO.2015.62.4544. PMID: 27114587 [PubMed - in process]

150. Rau RE, Carroll AJ, Heerema NA, Arland L, Carroll WL, **Winick** NJ, Raetz EA, Loh ML, Yang W, Relling MV, Dai Y, Devidas M, Hunger SP.  *Klinefelter syndrome and 47,XYY syndrome in children with B cell acute lymphoblastic leukaemia.* Br J Haematol. 2016 Jul 19. doi: 10.1111/bjh.14258. [Epub ahead of print] No abstract available. PMID: 27434379 [PubMed - as supplied by publisher]

151. Rodriguez V, Kairalla J, Salzer WL, Raetz EA, Loh ML, Carroll AJ, Heerema NA, Wood BL, Borowitz MJ, Burke MJ, Asselin BL, Devidas M, **Winick** NJ, Carroll WL, Hunger SP, Dreyer ZE. *A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1.* J Pediatr Hematol Oncol. 2016 Aug;38(6):409-17. doi: 10.1097/MPH.0000000000000589. PMID: 27299599 [PubMed - in process]

152. Matlawska-Wasowska K, Kang H, Devidas M, Wen J, Harvey RC, Nickl CK, Ness SA, Rusch M, Li Y, Onozawa M, Martinez C, Wood BL, Asselin BL, Chen IM, Roberts KG, Baruchel A, Soulier J, Dombret H, Zhang J, Larson RS, Raetz EA, Carroll WL, **Winick** NJ, Aplan PD, Loh ML, Mullighan CG, Hunger SP, Heerema NA, Carroll AJ, Dunsmore KP, Winter SS. *MLL rearrangements impact outcome in HOXA-deregulated T-lineage acute lymphoblastic leukemia: a Children's Oncology Group Study.* Leukemia. 2016 Sep;30(9):1909-12. doi: 10.1038/leu.2016.60. No abstract available. PMID: 26952838 [PubMed - in process]

153. Cohn SM, Pokala HR, Siegel JD, McClay JE, Leonard D, Kwon J, Timmons CF, **Winick** NJ.  *Application of a standardized screening protocol for diagnosis of invasive mold infections in children with hematologic malignancies.*  Support Care Cancer. 2016 Dec;24(12):5025-5033. PMID: 27518197 [PubMed - in process]

154. Balis FM, Womer RB, Berg S, **Winick N**, Adamson PC, Fox E; Children's Oncology Group Chemotherapy Standardization Task Force. *Dosing anticancer drugs in infants: Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force* Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26636. Epub 2017 May 16. PMID: 28509433 [PubMed - indexed for MEDLINE]

155. Chen P, Chu A, Zia H, Koduru P, Collins R, **Winick N**, Fuda F, Chen W*. CD25 Expression in B Lymphoblastic Leukemia/Lymphoma Predicts t(9;22)(q34;q11)/Philadelphia Chromosome Translocation (Ph) and Is Associated With Residual Disease in Ph-Negative Patients* Am J Clin Pathol. 2016 Nov 1;146(5):632-638. doi: 10.1093/ajcp/aqw178. PMID: 28430957 [PubMed - indexed for MEDLINE]

156. Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR, McCastlain K, Edmonson M, Pounds SB, Shi L, Zhou X, Ma X, Sioson E, Li Y, Rusch M, Gupta P, Pei D, Cheng C, Smith MA, Auvil JG, Gerhard DS, Relling MV, Winick NJ, Carroll AJ, Heerema NA, Raetz E, Devidas M, Willman CL, Harvey RC, Carroll WL, Dunsmore KP, Winter SS, Wood BL, Sorrentino BP, Downing JR, Loh ML, Hunger SP, Zhang J, Mullighan CG. *The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.* Nat Genet. 2017 Aug;49(8):1211-1218. doi: 10.1038/ng.3909. Epub 2017 Jul 3. PMID: 28671688 [PubMed - indexed for MEDLINE]

157. Lu Z, Xie J, Wu G, Shen J, Collins R, Chen W, Kang X, Luo M, Zou Y, Huang LJ, Amatruda JF, Slone T, **Winick** N, Scherer PE, Zhang CC.  *Fasting selectively blocks development of acute lymphoblastic leukemia via leptin-receptor upregulation*. Nat Med. 2017 Jan;23(1):79-90. doi: 10.1038/nm.4252. PMID: 27941793 [PubMed - in process]

158. Leger KJ, Leonard D, Nielson D, de Lemos JA, Mammen PP, **Winick** NJ. *Circulating microRNAs: Potential Markers of Cardiotoxicity in Children and Young Adults Treated With Anthracycline Chemotherapy*. J Am Heart Assoc. 2017 Apr 4;6(4). pii: e004653. doi: 10.1161/JAHA.116.004653. PMID: 28377429. P.1-25 [PubMed - in process]

159. Karol SE, Larsen E, Cheng C, Cao X, Yang W, Ramsey LB, Fernandez CA, McCorkle JR, Paugh SW, Autry RJ, Lopez-Lopez E, Diouf B, Jeha S, Pui CH, Raetz EA, **Winick** NJ, Carroll WL, Hunger SP, Loh ML, Devidas M, Evans WE, Yang JJ, Relling MV. *Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia.* Leukemia. 2017 Feb 10. doi: 10.1038/leu.2017.24. [Epub ahead of print] PMID: 28096535. P.1325-1332 [PubMed - as supplied by publisher]

160. Liu Y, Fernandez CA, Smith C, Yang W, Cheng C, Panetta JC, Kornegay N, Liu C, Ramsey LB, Karol SE, Janke LJ, Larsen EC, **Winick N**, Carroll WL, Loh ML, Raetz EA, Hunger SP, Devidas M, Yang JJ, Mullighan CG, Zhang J, Evans WE, Jeha S, Pui CH, Relling MV. *Genome-Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy.* Clin Pharmacol Ther. 2017 Jan 16. doi: 10.1002/cpt.629. [Epub ahead of print] PMID: 28090653. P.131-140 [PubMed – as supplied by publisher]

161. **Winick N**, Devidas M, Chen S, Maloney K, Larsen E, Mattano L, Borowitz MJ, Carroll A, Gastier-Foster JM, Heerema NA, Willman C, Wood B, Loh ML, Raetz E, Hunger SP, Carroll WL. *The Impact of initial cerebrospinal fluid findings on outcome among patients with NCI standard and high-risk B-lymphoblastic leukemia: A report from the Children’s Oncology Group.* J Clin Oncol. 2017 Aug 1;35(22):2527-2534. doi: 10.1200/JCO.2016.71.4774. Epub 2017 May 23.

162. Hardy KK, Embry L, Kairalla JA, Helian S, Devidas M, Armstrong D, Hunger S, Carroll WL, Larsen E, Raetz EA, Loh ML, Yang W, Relling MV, Noll RB, **Winick N**. [*Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Children's Oncology Group.*](https://www.ncbi.nlm.nih.gov/pubmed/28671857) J Clin Oncol. 2017 Aug 10;35(23):2700-2707. doi: 10.1200/JCO.2016.71.7587. Epub 2017 Jul 3. PMID: 28671857 [PubMed - indexed for MEDLINE]

163. Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR, McCastlain K, Edmonson M, Pounds SB, Shi L, Zhou X, Ma X, Sioson E, Li Y, Rusch M, Gupta P, Pei D, Cheng C, Smith MA, Auvil JG, Gerhard DS, Relling MV, **Winick NJ**, Carroll AJ, Heerema NA, Raetz E, Devidas M, Willman CL, Harvey RC, Carroll WL, Dunsmore KP, Winter SS, Wood BL, Sorrentino BP, Downing JR, Loh ML, Hunger SP, Zhang J, Mullighan CG. [*The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.*](https://www.ncbi.nlm.nih.gov/pubmed/28671688) Nat Genet. 2017 Aug;49(8):1211-1218. doi: 10.1038/ng.3909. Epub 2017 Jul 3. PMID: 28671688 [PubMed - indexed for MEDLINE}

164. Zheng DJ, Lu X, Schore RJ, Balsamo L, Devidas M, **Winick NJ**, Raetz EA, Loh ML, Carroll WL, Sung L, Hunger SP, Angiolillo AL, Kadan-Lottick NS. [*Longitudinal analysis of quality-of-life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial.*](https://www.ncbi.nlm.nih.gov/pubmed/29112230) Cancer. 2018 Feb 1;124(3):571-579. doi: 10.1002/cncr.31085. Epub 2017 Nov 7. PMID: 29112230 [PubMed - in process]

165.Burke MJ, Devidas M, Maloney K, Angiolillo A, Schore R, Dunsmore K, Larsen E, Mattano LA Jr, Salzer W, Winter SS, Carroll W, **Winick NJ**, Loh ML, Raetz E, Hunger SP, Bleyer A. [*Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials.*](https://www.ncbi.nlm.nih.gov/pubmed/29115886)Leuk Lymphoma. 2018 Jul;59(7):1624-1633. doi: 10.1080/10428194.2017.1397658. Epub 2017 Nov 8. PMID: 29115886 [PubMed - indexed for MEDLINE]

166.Salzer WL, Burke MJ, Devidas M, Chen S, Gore L, Larsen EC, Borowitz M, Wood B, Heerema NA, Carroll AJ, Hilden JM, Loh ML, Raetz EA, **Winick NJ**, Carroll WL, Hunger SP. [*Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131.*](https://www.ncbi.nlm.nih.gov/pubmed/29266189) Cancer. 2018 Mar 15;124(6):1150-1159. doi: 10.1002/cncr.31099. Epub 2017 Dec 19. PMID: 29266189 [PubMed - in process]

167.DiNofia AM, Seif AE, Devidas M, Li Y, Hall M, Huang YV, Cahen V, Hunger SP, **Winick NJ**, Carroll WL, Fisher BT, Larsen EC, Aplenc R. [*Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232.*](https://www.ncbi.nlm.nih.gov/pubmed/29274118) Cancer Med. 2018 Jan;7(1):3-12. doi: 10.1002/cam4.1206. Epub 2017 Dec 23. PMID: 29274118 [PubMed - in process]

168.Wood B, Wu D, Crossley B, Dai Y, Williamson D, Gawad C, Borowitz MJ, Devidas M, Maloney KW, Larsen E, **Winick N**, Raetz E, Carroll WL, Hunger SP, Loh ML, Robins H, Kirsch I. [*Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL.*](https://www.ncbi.nlm.nih.gov/pubmed/29284596) Blood. 2018 Mar 22;131(12):1350-1359. doi: 10.1182/blood-2017-09-806521. Epub 2017 Dec 28. PMID: 29284596 [PubMed - in process]

169.Barredo JC, Hastings C, Lu X, Devidas M, Chen Y, Armstrong D, **Winick N**, Wood BL, Yanofsky R, Loh M, Gastier-Foster JM, Jorstad DT, Marcus R, Ritchey K, Carrol WL, Hunger SP. [*Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study.*](https://www.ncbi.nlm.nih.gov/pubmed/29286562)Pediatr Blood Cancer. 2018 May;65(5):e26928. doi: 10.1002/pbc.26928. Epub 2017 Dec 29. PMID: 29286562 [PubMed - in process]

170.Qian M, Cao X, Devidas M, Yang W, Cheng C, Dai Y, Carroll A, Heerema NA, Zhang H, Moriyama T, Gastier-Foster JM, Xu H, Raetz E, Larsen E, **Winick N**, Bowman WP, Martin PL, Mardis ER, Fulton R, Zambetti G, Borowitz M, Wood B, Nichols KE, Carroll WL, Pui CH, Mullighan CG, Evans WE, Hunger SP, Relling MV, Loh ML, Yang JJ. [*TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children.*](https://www.ncbi.nlm.nih.gov/pubmed/29300620) J Clin Oncol. 2018 Feb 20;36(6):591-599. doi: 10.1200/JCO.2017.75.5215. Epub 2018 Jan 4. PMID: 29300620 [PubMed - in process]

171.Gupta S, Devidas M, Loh ML, Raetz EA, Chen S, Wang C, Brown P, Carroll AJ, Heerema NA, Gastier-Foster JM, Dunsmore KP, Larsen EC, Maloney KW, Mattano LA Jr, Winter SS, **Winick NJ**, Carroll WL, Hunger SP, Borowitz MJ, Wood BL. [*Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG).*](https://www.ncbi.nlm.nih.gov/pubmed/29472723) Leukemia. 2018 Jun;32(6):1370-1379. doi: 10.1038/s41375-018-0039-7. Epub 2018 Feb 23. PMID: 29472723 [PubMed - in process]

172.Churchman ML, Qian M, Te Kronnie G, Zhang R, Yang W, Zhang H, Lana T, Tedrick P, Baskin R, Verbist K, Peters JL, Devidas M, Larsen E, Moore IM, Gu Z, Qu C, Yoshihara H, Porter SN, Pruett-Miller SM, Wu G, Raetz E, Martin PL, Bowman WP, **Winick N**, Mardis E, Fulton R, Stanulla M, Evans WE, Relling MV, Pui CH, Hunger SP, Loh ML, Handgretinger R, Nichols KE, Yang JJ, Mullighan CG. [*Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia.*](https://www.ncbi.nlm.nih.gov/pubmed/29681510) Cancer Cell. 2018 May 14;33(5):937-948.e8. doi: 10.1016/j.ccell.2018.03.021. Epub 2018 Apr 19. PMID: 29681510 [PubMed - indexed for MEDLINE]

173.Slayton WB, Schultz KR, Kairalla JA, Devidas M, Mi X, Pulsipher MA, Chang BH, Mullighan C, Iacobucci I, Silverman LB, Borowitz MJ, Carroll AJ, Heerema NA, Gastier-Foster JM, Wood BL, Mizrahy SL, Merchant T, Brown VI, Sieger L, Siegel MJ, Raetz EA, **Winick NJ**, Loh ML, Carroll WL, Hunger SP. [*Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.*](https://www.ncbi.nlm.nih.gov/pubmed/29812996) J Clin Oncol. 2018 Aug 1;36(22):2306-2314. doi: 10.1200/JCO.2017.76.7228. Epub 2018 May 29. PMID: 29812996 [PubMed - in process]

174.Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Gaynon PS, Borowitz MJ, Loh ML, Rabin KR, Raetz EA, Zweidler-Mckay PA, **\*Winick NJ**, \*Carroll WL, \*Hunger SP. [*Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization.*](https://www.ncbi.nlm.nih.gov/pubmed/30138085) J Clin Oncol. 2018 Oct 10;36(29):2926-2934. doi: 10.1200/JCO.2018.77.7250. Epub 2018 Aug 23. Erratum in: [J Clin Oncol. 2019 Mar 20;37(9):761](https://www.ncbi.nlm.nih.gov/pubmed/30875487). PMID: 30138085 [PubMed - in process] \* Shared senior authorship

175. Qian M, Xu H, Perez-Andreu V, Roberts KG, Zhang H, Yang W, Zhang S, Zhao X, Smith C, Devidas M, Gastier-Foster JM, Raetz E, Larsen E, Burchard EG, **Winick N**, Bowman WP, Martin PL, Borowitz M, Wood B, Antillon-Klussmann F, Pui CH, Mullighan CG, Evans WE, Hunger SP, Relling MV, Loh ML, Yang JJ. [*Novel susceptibility variants at the <i>ERG</i> locus for childhood acute lymphoblastic leukemia in Hispanics.*](https://www.ncbi.nlm.nih.gov/pubmed/30510082) Blood. 2019 Feb 14;133(7):724-729. doi: 10.1182/blood-2018-07-862946. Epub 2018 Dec 3. PMID: 30510082 [PubMed - in process]

176.Burke MJ, Salzer WL, Devidas M, Dai Y, Gore L, Hilden JM, Larsen E, Rabin KR, Zweidler-McKay PA, Borowitz MJ, Wood B, Heerema NA, Carroll AJ, **Winick N**, Carroll WL, Raetz EA, Loh ML, Hunger SP. [*Replacement of cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide /etoposide during Consolidation/Delayed Intensification does not improve outcome for pediatric B-ALL: a report from the COG.*](https://www.ncbi.nlm.nih.gov/pubmed/30545921) Haematologica. 2018 Dec 13. pii: haematol.2018.204545. doi: 10.3324/haematol.2018.204545. [Epub ahead of print] PMID: 30545921 [PubMed - as supplied by publisher]

177. Galimberti S, Devidas M, Lucenti A, Cazzaniga G, Möricke A, Bartram CR, Mann G, Carroll W, Winick N, Borowitz M, Wood B, Basso G, Conter V, Zimmermann M, Suciu S, Biondi A, Schrappe M, Hunger SP, Valsecchi MG. JNCI Cancer Spectr. [*Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia.*](https://www.ncbi.nlm.nih.gov/pubmed/31360884) 2018 Dec 19;2(4):pky069. doi: 10.1093/jncics/pky069. eCollection 2018 Oct. PMID 31360884 [PubMed - as supplied by publisher]

178.Schore RJ, Devidas M, Bleyer A, Reaman GH, **Winick N**, Loh ML, Raetz EA, Carroll WL, Hunger SP, Angiolillo AL. *Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4.* Leuk Lymphoma. 2019 Jan 10:1-9. doi: 10.1080/10428194.2018.1542146. [Epub ahead of print].PMID: 30626253 [PubMed - as supplied by publisher]

179. McNeer JL, Devidas M, Dai Y, Carroll AJ, Heerema NA, Gastier-Foster JM, Kahwash SB, Borowitz MJ, Wood BL, Larsen E, Maloney KW, Mattano L, **Winick NJ**, Schultz KR, Hunger SP, Carroll WL, Loh ML, Raetz EA. [*Hematopoietic Stem Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group.*](https://www.ncbi.nlm.nih.gov/pubmed/30742559) J Clin Oncol. 2019 Feb 11:JCO1800884. doi: 10.1200/JCO.18.00884. [Epub ahead of print] PMID: 30742559 [PubMed - as supplied by publisher]

180. Robinson KM, Yang W, Karol SE, Kornegay N, Jay D, Cheng C, Choi JK, Campana D, Pui CH, Wood B, Borowitz MJ, Gastier-Foster J, Larsen EC, **Winick N**, Carroll WL, Loh ML, Raetz EA, Hunger SP, Devidas M, Mardis ER, Fulton RS, Relling MV, Jeha S. [*No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy.*](https://www.ncbi.nlm.nih.gov/pubmed/30848065) Pediatr Blood Cancer. 2019 Mar 7:e27681. doi: 10.1002/pbc.27681. [Epub ahead of print]. PMID: 30848065 [PubMed - as supplied by publisher]

181. Matloub Y, Rabin KR, Ji L, Devidas M, Hitzler J, Xu X, Bostrom BC, Stork LC, Winick N, Gastier-Foster JM, Heerema NA, Stonerock E, Carroll WL, Hunger SP, Gaynon PS.[*Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology Group.*](https://www.ncbi.nlm.nih.gov/pubmed/31160295)Blood Adv. 2019 Jun 11;3(11):1647-1656. doi: 10.1182/bloodadvances.2019032094. PMID: 3116295 [PubMed - as supplied by publisher]

182. Li L, Sajdyk T, Smith EML, Chang CW, Li C, Ho RH, Hutchinson R, Wells E, Skiles JL, **Winick N**, Martin PL, Renbarger JL. [*Genetic Variants Associated With Vincristine-Induced Peripheral Neuropathy in Two Populations of Children With Acute Lymphoblastic Leukemia.*](https://www.ncbi.nlm.nih.gov/pubmed/30506673) Clin Pharmacol Ther. 2019 Jun;105(6):1421-1428 doi: 10.1002/cpt.1324. [Epub ahead of print] PMID: 30506673 [PubMed - as supplied by publisher]

183. Carroll AJ, Shago M, Mikhail FM, Raimondi SC, Hirsch BA, Loh ML, Raetz EA, Borowitz MJ, Wood BL, Maloney KW, Mattano LA Jr, Larsen EC, Gastier-Foster J, Stonerock E, Ell D, Kahwash S, Devidas M, Harvey RC, Chen IL, Willman CL, Hunger SP, Winick NJ, Carroll WL, Rao KW, Heerema NA. Cancer Genet. [*Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children's Oncology Group.*](https://www.ncbi.nlm.nih.gov/pubmed/31425927) 2019 Oct;238:62-68. doi: 10.1016/j.cancergen.2019.07.009. Epub 2019 Jul 30. PMID:31425927

184. Brown AL, de Smith AJ, Gant VU, Yang W, Scheurer ME, Walsh KM, Chernus JM, Kallsen NA, Peyton SA, Davies GE, Ehli EA, Winick N, Heerema NA, Carroll AJ, Borowitz MJ, Wood BL, Carroll WL, Raetz EA, Feingold E, Devidas M, Barcellos LF, Hansen HM, Morimoto L, Kang AY, Smirnov I, Healy J, Laverdière C, Sinnett D, Taub JW, Birch JM, Thompson P, Spector LG, Pombo-de-Oliveira MS, DeWan AT, Mullighan CG, Hunger SP, Pui CH, Loh ML, Zwick ME, Metayer C, Ma X, Mueller BA, Sherman SL, Wiemels JL, Relling MV, Yang JJ, Lupo PJ, Rabin KR.

Blood. [*Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome.*](https://www.ncbi.nlm.nih.gov/pubmed/31350265)2019 Oct 10;134(15):1227-1237. doi: 10.1182/blood.2018890764. PMID: 3135265

185. **Winick N**, Martin PL, Devidas M, Shuster J, Borowitz MJ, Paul Bowman W, Larsen E, Pullen J, Carroll A, Willman C, Hunger SP, Carroll WL, Camitta BM. [*Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group Studies P9904 and P9905.*](https://www.ncbi.nlm.nih.gov/pubmed/31728054)Leukemia. 2020 Apr;34(4):1006-1016. doi: 10.1038/s41375-019-0642-2. Epub 2019 Nov 14. PMID: 31728054

186. Raetz EA, Loh ML, Devidas M, Maloney K, Mattano LA Jr, Larsen E, Carroll A, Heerema NA, Gastier-Foster JM, Wood B, Borowitz MJ, **Winick N**, Hunger SP, Carroll WL.Haematologica. [*Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Children's Oncology Group.*](https://www.ncbi.nlm.nih.gov/pubmed/31004024)2019 Nov;104(11):e517-e520. doi: 10.3324/haematol.2018.215616. Epub 2019 Apr 19. No abstract available. PMID: 31004024 [PubMed - as supplied by publisher]

187. Maloney KW, Devidas M, Wang C, Mattano LA, Friedmann AM, Buckley P, Borowitz MJ, Carroll AJ, Gastier-Foster JM, Heerema NA, Kadan-Lottick N, Loh ML, Matloub YH, Marshall DT, Stork LC, Raetz EA, Wood B, Hunger SP, Carroll WL, **Winick NJ**.

[*Outcome in Children with Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331.*](https://www.ncbi.nlm.nih.gov/pubmed/31825704)J Clin Oncol. 2020 Feb 20;38(6):602-612. doi: 10.1200/JCO.19.01086. Epub 2019 Dec 11.

PMID: 31825704

188. Gupta S, Wang C, Raetz EA, Schore R, Salzer WL, Larsen EC, Maloney KW, Mattano LA Jr, Carroll WL, **Winick NJ**, Hunger SP, Loh ML, Devidas M. *Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group* J Clin Oncol. 2020 Jun 10;38(17):1897-1905. doi: 10.1200/JCO.19.03024. Epub 2020 Apr 10.

PMID: 32275469

189. Salzer WL, Burke MJ, Devidas M, Dai Y, Hardy KK, Kairalla JA, Gore L, Hilden JM, Larsen E, Rabin KR, Zweidler-McKay PA, Borowitz MJ, Wood B, Heerema NA, Carroll AJ, **Winick N**, Carroll WL, Raetz EA, Loh ML, Hunger SP. *Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131* J Clin Oncol. 2020 Aug 10;38(23):2628-2638. doi: 10.1200/JCO.19.02892. Epub 2020 Jun 4.

PMID: 32496902

190. Zhang H, Liu AP, Devidas M, Lee SHR, Cao X, Pei D, Borowitz M, Wood B, Gastier-Foster JM, Dai Y, Raetz E, Larsen E, **Winick N**, Bowman WP, Karol S, Yang W, Martin PL, Carroll WL, Pui CH, Mullighan CG, Evans WE, Cheng C, Hunger SP, Relling MV, Loh ML, Yang JJ. *Association of GATA3 polymorphisms with minimal residual disease and relapse risk in childhood acute lymphoblastic leukemia* J Natl Cancer Inst. 2021 Apr 6; 113(4):408-417. doi: 10.1093/jnci/djaa138. PMID: 32894760

191. Hayashi RJ, Winter SS, Dunsmore KP, Devidas M, Chen Z, Wood BL, Hermiston ML, Teachey DT, Perkins SL, Miles RR, Raetz EA, Loh ML, **Winick NJ**, Carroll WL, Hunger SP, Lim MS, Gross TG, Bollard CM. *Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434* J Clin Oncol. 2020 Sep 10;38(26):3062-3070. doi: 10.1200/JCO.20.00531. Epub 2020 Jun 17.

PMID: 32552472

192. Goldberg J, Sulis ML, Bender J, Jeha S, Gardner R, Pollard J, Aquino V, Laetsch T, **Winick N**, Fu C, Marcus L, Sun W, Verma A, Burke M, Ho P, Manley T, Mody R, Tcheng W, Thomson B, Park J, Sposto R, Messinger Y, Hijiya N, Gaynon P, Barredo J. *A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies* Pediatr Hematol Oncol. 2020 Sep;37(6):465-474. doi: 10.1080/08880018.2020.1752869. Epub 2020 Apr 27. PMID: 32338562 Clinical Trial.

193. Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, \*Carroll AJ, Heerema NA, Asselin BL, Rabin KR, Zweidler-Mckay PA, Raetz EA, Loh ML, Schultz KR, \***Winick NJ**, Carroll WL, \*Hunger SP. *Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia* J Clin Oncol. 2020 Oct 1;38(28):3282-3293. doi: 10.1200/JCO.20.00256. Epub 2020 Aug 19. PMID: 32813610

194. Yang W, Devidas M, Liu Y, Smith C, Dai Y, **Winick N**, Hunger SP, Loh ML, Raetz EA, Larsen E, Carroll WL, Winter SS, Dunsmore KP, Mattano LA, Relling MV, Karol SE. *Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations* Blood. 2021 Mar 18;137(11):1550-1152. doi: 10.1182/blood.2020008471. PMID: 33106839. No abstract available.

195. Lew G, Chen Y, Lu X, Rheingold SR, Whitlock JA, Devidas M, Hastings CA, **Winick NJ**, Carroll WL, Wood BL, Borowitz MJ, Pulsipher MA, Hunger SP. *Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433* Haematologica. 2021 Jan 1;106(1):46-55. doi: 10.3324/haematol.2019.237230.PMID: 32001530

196. Angiolillo AL, Schore RJ, Kairalla JA, Devidas M, Rabin KR, Zweidler-McKay P, Borowitz MJ, Wood B, Carroll AJ, Heerema NA, Relling MV, Hitzler J, Lane AR, Maloney KW, Wang C, Bassal M, Carroll WL, **Winick NJ**, Raetz EA, Loh ML, Hunger SP. *Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932* J Clin Oncol. 2021 Jan 7: JCO2000494. doi: 10.1200/JCO.20.00494. Online ahead of print. PMID: 33411585

197. Dunsmore KP, Winter SS, Devidas M, **Winick NJ**, Carroll WL, Hunger SP *Reply to A. K. Agrawal et al* J Clin Oncol. 2021 Jan 14:JCO2003370. doi: 10.1200/JCO.20.03370. Online ahead of print. PMID: 33444082 No abstract available.

198. Murphy CC, Lupo PJ, Roth ME, **Winick NJ**, Pruitt SL. *Disparities in cancer survival among adolescents and young adults: a population-based study of 88,000 patients* J Natl Cancer Inst. 2021 Jan 23:djab006. doi: 10.1093/jnci/djab006. Online ahead of print.

PMID: 33484568

199. Advani AS, Larsen E, Laumann K, Luger SM, Liedtke M, Devidas M, Chen Z, Yin J, Foster MC, Claxton D, Coffan K, Tallman MS, Appelbaum FR, Erba H, Stone RM, Hunger SP, McNeer JL, Loh ML, Raetz E, **Winick N**, Carroll W, Larson RA, Stock W. *Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia* Blood Adv. 2021 Jan 26;5(2):504-512. doi: 10.1182/bloodadvances.2020002439. PMID: 33496745

200. Jacola LM, Baran J, Noll RB, Willard VW, Hardy KK, Embry L, Hullmann SE, Larsen EC, **Winick N**, Kairalla JA *Adaptive functioning and academic achievement in survivors of childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group* Pediatr Blood Cancer. 2021 Jan 31:e28913. doi: 10.1002/pbc.28913. Online ahead of print. PMID: 33522102

 201. Henning E, Germann JN, Holder N, Nakonezny P, Loftin S, Redondo-Doan B, Jones L, Petty LA, Pratt C, Issacs T, Liu K, **Winick N**. *The impact of family bereavement interventions: Qualitative feedback identifies needs.* Clin Practice in Ped 2021 9(3): 283-295. Psycholhttps://doi.org/10.1037/cpp0000416

202. Rau RE, Dai Y, Devidas M, Rabin KR, Zweidler-McKay P, Angiolillo A, Hardy RJ, Burke MJ, Salzer WL, Heerema NA, Carroll AJ, **Winick NJ**, Hunger SP, Raetz EA, Loh ML, Wood BL, Boorowitz MJ. *Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children’s Oncology Group* Pediatr Blood Cancer. 2021 Apr;68(4):e28929. doi:10.1002/pbc.28929. Epub 2021 Feb 9. PMID: 33559396

203. Mattano LA Jr, Devidas M, Maloney KW, Wang C, Friedmann AM, Buckley P, Borowitz MJ, Carroll AJ, Gastier-Foster JM, Heerema NA, Kadan-Lottick NS, Matloub YH, Marshall DT, Stork LC, Loh ML, Raetz EA, Wood BL, Hunger SP, Carroll WL, **Winick NJ**. *Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children’s Oncology Group Trial AALL0331* J Clin Oncol. 2021 May 10;39(14):1540-1552. doi: 10.1200/JCO.20.02370. Epub 2021 Mar 19. PMID: 33739852

204. Brown PA, Kairalla JA, Hilden JM, Dreyer ZE, Carroll AJ, Heerema NA, Wang C, Devidas M, Gore L, Salzer WL, **Winick NJ**, Carroll WL, Raetz EA, Borowitz MJ, Small D, Loh ML, Hunger SP. *Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranfed infants acute lymphoblastic leukemia: Children’s Oncology Group trial AALL063* Leukemia. 2021 May;35(5):1527. doi: 10.1038/s41375-021-01245-x. PMID: 33846544 No abstract available.

205. Brown PA, Kairalla JA, Hilden JM, Dreyer ZE, Carroll AJ, Heerema NA, Wang C, Devidas M, Gore L, Salzer WL, **Winick NJ**, Carroll WL, Raetz EA, Borowitz MJ, Small D, Loh ML, Hunger SP. *FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearrangd infant acute lymphoblastic leukemia: Children’s Oncology Group trail AALL0631* Leukemia. 2021 May;35(5):1279-1290. doi: 10.1038/s41375-021-01177-6. Epub 2021 Feb 23. PMID: 33623141. Clinical Trial.

206. Andres-Jensen L, Attarbaschi A, Bardi E, Barzilai-Birenboim S, Bhojwani D, Hagleitner MM, Halsey C, Harila-Saari A, van Litsenburg RRL, Hudson MM, Jeha S, Kato M, Kremer L, Mlynarski W, Moricke A, Pieters R, Piette C, Raetz E, Ronceray L, Toro C, Grazia Valsecchi M, Vrooman LM, Weinreb S, **Winick N**, Schmiegelow K, Ponte di Legno Sever Toxicity Working Group. *Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukemia* Lancet Haematol. 2021 Jul;8(7):e513-e523. doi: 10.1016/S2352-3026(21)00136-8. PMID: 34171282 Review.

207. Xu X, Paxton CN, Hayashi RJ, Dunsmore KP, Winter SS, Hunger SP, **Winick NJ**, Carroll WL, Loh ML, Devidas M, Gross TG, Bollard CM, Perkins SL, Miles RR. *Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma* Blood Adv. 2021 Jul 27;5(14):2890-2900. doi: 10.1182/bloodadvances.2021004334. PMID: 34297047

208. Lui Y, Yang W, Smith CA, Cheng C, Karol SE, Larsen EC, **Winick N**, Carroll WL, Loh ML, Raetz EA, Hunger SP, Winter SS, Dunsmore KP, Devidas M, Yang JJ, Evans WE, Jeha S, Pui CH, Inaba H, Relling MV. *Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity* Clin Pharmacol Ther. 2021 Sep;110(3):794-802. doi: 10.1002/cpt.2241. Epub 2021 Apr 21. PMID: 33768542

209. Getz KD, Szymczak JE, Li Y, Madding R, Huang YV, Aftandilian C, Arnold SD, Bona KO, Caywood E, Collier AB, Gramatges MM, Henry M, Lotterman C, Maloney K, Mian A, Mody R, Morgan E, Raetz EA, Rubnitz J, Verma A, **Winick N**, Wilkes JJ, Yu JC, Fisher BT, Aplenc R. *Medical Outcomes, Quality of Life, and Family Perceptions for Outpatient vs Inpatient Neutropenia Management After Chemotherapy for Pediatric Acute Myeloid Leukemia* JAMA Netw Open. 2021 Oct 1;4(10):e2128385. doi: 10.1001/jamanetworkopen.2021.28385. PMID: 34709389.

210. Burke MJ, Devidas M, Chen Z, Salzer WL, Raetz EA, Rabin KR, Heerema NA, Carroll AJ, Gastier-Foster JM, Borowitz MJ, Wood BL, **Winick NJ**, Carroll WL, Hunger SP, Loh ML, Larsen EC. *Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children’s Oncology Group Study AALL0232* Leukemia. 2022 Mar;36(3):648-655. doi: 10.1038/s41375-021-01460-6. Epub 2021 Nov 1. PMID: 34725453 Clinical Trial.

211. Hastings C. Chen Y, Devidas M, Ritchey AK, Winick NJ, Carroll WL, Hunger SP, Wood BL, Marcus RB, Barredo JC. *Late isolated central nervous system relapse in childhood B-cell acute lymphoblastic leukemia treated with intensified systemic therapy and delayed reduced dose cranial radiation: A report from the Children’s Oncology Group study AALL02P2* Pediatr Blood Cancer. 2021 Dec;68(12):e29256. doi: 10.1002/pbc.29256. Epub 2021 Jul 24. PMID: 34302704.

212. Elgarten CW, Otto WR, Shenton L, Stein MT, Horowitz J, Aftandilian C, Arnold SD, Bona KO, Caywood E, Collier AB, Gramatges MM, Henry M, Lotterman C, Maloney K, Modi AJ, Mian A, Mody R, Morgan E, Raetz EA, Verma A, **Winick N**, Wilkes JJ, Yu JC, Aplenc R, Fisher BT, Getz KD. *Risk of bacterial bloodstream infection does not vary by central-line type during neutropenic periods in pediatric acute myeloid leukemia* Infect Control Hosp Epidemiol. 2023 Apr 25:1-8. doi:10-1017/ice.2022.82. PMID: 35465865

213. Gupta S, Teachey DT, Chen Z, Rabin KR, Dunsmore KP, Larsen EC, Maloney KW, Mattano LA Jr, Winter SS, Carroll AJ, Heerema NA, Borowitz MJ, Wood BL, Carroll WL, Raetz EA, **Winick NJ**, Loh ML, Hunger SP, Devidas M. *Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children’s Oncology Group report* Cancer. 2022 May 1;128(9):1863-18970. doi: 10.1002/cncr.34150. Epub 2022 Feb 24. PMID: 3501611

214. Rodwin RL, Kairalla JA, Hibbitts E, Devidas M, Whitley MK, Mohrmann CE, Schore RJ, Raetz E, **Winick NJ**, Hunger SP, Loh ML, Hockenberry MJ, Angiolillo AL, Ness KK, Kadan-Lottick NS. *Persistence of chemotherapy-induced peripheral neurotherapy despite vincristine reduction in childhood b-acute lymphoblastic leukemia* J Natl Cancer Inst. 2022 May 12:djac095. doi: 10.1093/jnci/djac095. Online ahead of print. PMID: 35552709

215. Guest EM, Kairalla JA, Hilden JM, Dreyer ZE, Carroll AJ, Heerema NA, Wang CY, Devidas M, Gore L, Salzer WL, **Winick NJ**, Carroll WL, Raetz EA, Borowitz M, Loh ML, Hunger SP, Brown PA. *Outstanding outcomes in infants with KMT2A-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children’s Oncology Group AALL0631 trial* Haematologica. 2022 May 1;107(5):1205-1208. doi:10.3324/haematol.2021.280146. PMID: 35172563. Clinical Trial. No abstract available.

216. El-Behadli AF, Germann JN, Pratt C, Acosta D, Montiel-Esparza R, Alvarez N, **Winick N\***, Faith MA\*. *Culturally Adapted Motivational Interviewing for Pediatric Acute Lymphoblastic Leukemia Adherence: Feasibility and Acceptability.* Clinical Practice in Pediatric Psychology. 2022 July 28 Advance online publication. <http://dx.doi.org/10.1037/cpp0000447> \* Co-senior authors

217. Brady SW, Roberts KG, Gu Z, Shi L, Pounds S, Pei D, Cheng C, Dai Y, Devidas M, Qu C, Hill AN, Payne-Turner D, Ma X, Iacobucci I, Baviskar P, Wei L, Arunachalam S, Hagiwara K, Liu Y, Flasch DA, Liu Y, Parker M, Chen X, Elsayed AH, Pathak O, Li Y, Fan Y, Michael JR, Rusch M, Wilkinson MR, Foy S, Hedges DJ, Newman S, Zhou X, Wang J, Reilly C, Sioson E, Rice SV, Pastor Loyola V, Wu G, Rampersaud E, Reshmi SC, Gastier-Foster J, Guidry Auvil JM, Gesuwan P, Smith MA, **Winick N**, Carroll AJ, Heerema NA, Harvey RC, Willman CL, Larsen E, Raetz EA, Borowitz MJ, Wood BL, Carroll WL, Zweidler-McKay PA, Rabin KR, Mattano LA, Maloney KW, Winter SS, Burke MJ, Salzer W, Dunsmore KP, Angiolillo AL, Crews KR, Downing JR, Jeha S, Pui CH, Evans WE, Yang JJ, Relling MV, Gerhard DS, Loh ML, Hunger SP, Zhang J, Mullighan CG. *The genomic landscape of pediatric acute lymphoblastic leukemia.* Nat Genet. 2022 Sep;54(9):1376-1389. doi: 10.1038/s41588-022-01159-z. Epub 2022 Sep 1. PMID: 36050548

218. Schore RJ, Angiolillo AL, Kairalla JA, Devidas M, Rabin KR, Zweidler-McKay P, Borowitz MJ, Wood B, Carroll AJ, Heerema NA, Relling MV, Hitzler J, Kadan-Lottick NS, Maloney K, Wang C, Carroll WL, **Winick NJ,** Raetz EA, Loh ML, Hunger SP. *Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932.* Leukemia. 2023 Jun;37(6):1375-1378. doi: 10.1038/s41375-023-01870-8. Epub 2023 Mar 25.PMID: 36966262 No abstract available.

219. Robinson BW, Kairalla JA, Devidas M, Carroll AJ, Harvey RC, Heerema NA, Willman CL, Ball AR, Woods EC, Ballantyne NC, Urtishak KA, Behm FG, Reaman GH, Hilden JM, Camitta BM, **Winick NJ**, Pullen J, Carroll WL, Hunger SP, Dreyer ZE, Felix CA. *KMT2A partner genes in infant acute lymphoblastic leukemia have prognostic significance and correlate with age, white blood cell count, sex, and central nervous system involvement: a Children's Oncology Group P9407 trial study.* Haematologica. 2023 Mar 2. doi: 10.3324/haematol.2022.281552. Online ahead of print.

PMID: 36861410

220. Schore RJ, Angiolillo AL, Kairalla JA, Devidas M, Rabin KR, Zweidler-McKay P, Borowitz MJ, Wood B, Carroll AJ, Heerema NA, Relling MV, Hitzler J, Kadan-Lottick NS, Maloney K, Wang C, Carroll WL, **Winick NJ**, Raetz EA, Loh ML, Hunger SP. *Correction: Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932.* Leukemia. 2023 Jun;37(6):1406. doi: 10.1038/s41375-023-01921-0. PMID: 37157018 No abstract available.

221. Gossai NP, Devidas M, Chen Z, Wood BL, Zweidler-McKay PA, Rabin KR, Loh ML, Raetz EA, **Winick NJ,** Burke MJ, Carroll AJ, Esiashvili N, Heerema NA, Carroll WL, Hunger SP, Dunsmore KP, Winter SS, Teachey DT. *Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children's Oncology Group report.*

Blood. 2023 Apr 13;141(15):1802-1811. doi: 10.1182/blood.2022018653.

PMID: 36603187 Clinical Trial.

222. Hardy KK, Kairalla JA, Gioia AR, Weisman HS, Gurung M, Noll RB, Hinds PS, Hibbitts E, Salzer WL, Burke MJ, **Winick NJ,** Embry L. *Impaired neurocognitive functioning 3 months following diagnosis of high-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group.*  Pediatr Blood Cancer. 2023 Jul;70(7):e30350. doi: 10.1002/pbc.30350. Epub 2023 May 2. PMID: 37129114

223. Pestian T, Awtrey E, Kanov J, **Winick N,** Thienprayoon R. *The impact of organizational compassion in health care on clinicians: A scoping review.* Worldviews Evid Based Nurs. 2023 Jun 20. doi: 10.1111/wvn.12664. Online ahead of print.

PMID: 37340547

224. Gupta S, Dai Y, Chen Z, Winestone LE, Teachey DT, Bona K, Aplenc R, Rabin KR, Zweidler-McKay P, Carroll AJ, Heerema NA, Gastier-Foster J, Borowitz MJ, Wood BL, Maloney KW, Mattano LA Jr, Larsen EC, Angiolillo AL, Burke MJ, Salzer WL, Winter SS, Brown PA, Guest EM, Dunsmore KP, Kairalla JA, **Winick NJ,** Carroll WL, Raetz EA, Hunger SP, Loh ML, Devidas M. *Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials.* Lancet Haematol. 2023 Feb;10(2):e129-e141. doi: 10.1016/S2352-3026(22)00371-4. PMID: 36725118

Reviews, Chapters, Monographs and Editorials

1. Kamen BA,  **Winick NJ**: High Dose MTX Therapy: Insecure Rationale? Biochem Pharmacol 1988;37:2713-2715.
2. **Winick NJ**: Severe Anemia. Essentials of Pediatric Intensive Care. Levin DL (ed), Morriss FC (ed). Quality Med Publishing, Inc. St Louis, 1990;393-395.
3. **Winick NJ**: Blood Product Transfusions. Essentials of Pediatric Intensive Care. Levin DL, Morriss FC, (ed). Quality Med Publishing, Inc. St. Louis, 1990;967-971.
4. Bernini JC, **Winick NJ**: Severe Anemia. Essentials of Pediatric Intensive Care. Levin DL, Morriss FC, (ed). Churchill Livingstone, Inc. New York, 1997;492-497.
5. **Winick NJ**: Demakos EP: Teniposide. Outline of Oncology Therapeutics: Ratain MJ, Tempero M, Skosey C, (ed). W.B. Saunders, Orlando, FL, 2001;34.
6. **Winick NJ**, Carroll WL, and Hunger SP. Childhood leukemia—new advances and challenges. N Engl J Med 2004 Aug 5;351(6):601-3.
7. **Winick NJ**, Raetz EA, Ritter J, Carroll WJ: Acute Lymphoblastic Leukemia: in Cancer in Children. Carrol, WJ, and Finley J (eds). Jones and Bartlett, Inc, 2008.
8. **Winick NJ**: [Is immunization necessary after therapy for acute lymphoblastic leukemia (ALL) has been completed?](http://www.ncbi.nlm.nih.gov/pubmed/19653293?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum) Pediatr Blood Cancer. 2009 Aug 3. [Epub ahead of print] 2009 Dec; 53 (6): 922-23.
9. **Winick NJ**: Neurocogntive outcome in survivors of pediatric cancer. Curr Opin Pediatri 2011 Feb; 23 (1): 27-33.
10. Chen K, Bach A, Shoup A, **Winick NJ**: Invited reply to amikacin ototoxicity in children with cancer: the problem is the administration schedule. Pediatr Blood Cancer. 2014 Feb;61(2):191.doi: 10.1002/pbc.24737. Epub 2013 Aug 16. No abstract available. PMID: 23955849 [PubMed – indexed for MEDLINE].
11. **Winick NJ**. It takes a village. Blood. 2014 Oct 9;124(15):2316-7. doi: 10.1182/blood-2014-05-576900. PMID: 25301330 [PubMed - in process].
12. **Winick NJ.** The evolution of central nervous system prophylaxis for patients with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015 Nov;62(11):1877-8. doi: 10.1002/pbc.25658. Epub 2015 Jul 2. No abstract available. PMID: 26139230 [PubMed - as supplied by publisher]

1. **Winick N.** Drugs don’t work in patients who don’t take them. Comment on Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children’s Oncology Group Study AALL03N1 by Landier et al. JCO Podcast March 24, 2017

Books/Textbooks

|  |  |
| --- | --- |
|  |  |
|  |  |

Case Reports

|  |  |
| --- | --- |
|  | Haruda F, Friedman JH, Ganti SR, Hoffman () N, Chutorian AM: Rapid resolution of organic mental syndrome in sickle cell anemia in response to exchange transfusion. Neurology 1981;31:1015-1016. |
|  | Squires Jr RH, Weinberg AG, Zwiener RJ, N: Langerhans' cell histiocytosis presenting with hepatic dysfunction. J Pediatr Gastroenterol Nutr 1993;16:190-193. |
|  | Mustafa MM, Weitman SD, NJ, Bellini WJ, Timmons CF, Siegel JD: Subacute measles encephalitis in the young immunocompromised host: Report of two cases diagnosed by polymerase chain reaction and treated with ribavirin and review of the literature. Clin Infec Dis 1993;l16:654-660. |
|  | Keljo DJ, Weinberg AG, N, Tomlinson G: Rectal cancer in an 11-year old girl with hyperplastic polyposis. J Pediatr Gastroenterol Nutr 1999;28:327-332. |
|  | Scothorn DJ, NJ, Timmons CF, Aquino VM: Rapidly fatal acute bacterial myocarditis in a non-neutropenic child with acute lymphoblastic leukemia in remission. Journal of Pediatric Hematology/Oncology 2002;24:662-665. |

Letters to the Editor

|  |  |
| --- | --- |
|  |  **N**, Buchanan GR, Kamen BA: Secondary acute myeloid leukemia in Hispanic children. J Clin Oncol 1993;11:1433. |
|  | Kamen BA,  **N**, Holcenberg JS: Oral versus intravenous methotrexate: Another opinion. J Clin Oncol 1998;16:2283-2285. |
|  | Chen K, Bach A, Shoup A, **Winick N.** Invited reply to Amikacin ototoxicity in children with cancer: The problem is the administration schedule. Pediatr Blood Cancer. 2014:61:191. |
|  | Hardy KK, Embry LM, Kairalla JA, Helian S, Devidas M, Armstrong FD, Hunger S, Carroll WL, Larsen E, Raetz EA, Loh ML, Yang W, Relling MV, Noll RB, **Winick N**. Reply to I.J. Cohen. J Clin Oncology. 2017 Dec 10;35(35):3989-3991. Doi: 10.1200/JCO.2017.75.7252. Epub 2017 Oct 18. No abstract available. PMID: 29045162 [PubMed - in process] |

Proceedings of Meetings

|  |  |
| --- | --- |
|  |  **NJ**, Krakower G, Kamen BA: Metabolism of MTX to polyglutamy derivatives and relationship to folate pools in vivo. Proc 2nd Workshop on Folyl and Anti-Folyl Polyglutamates. Goldman ID (ed). Praeger Publ. New York, 1985;297-307. |

Clinical Practice Guidelines

|  |  |
| --- | --- |
|  |  |
|  |  |

**Non-peer reviewed scientific or medical publications/materials in print or other media**

**Published Abstracts**

1. Hoffman,  **N**, Miller L, Steinhurz L, Hancock C, Miller D, Steinherz P, Tan C: A Phase I study of 4-demethoxydaunorubicin (4-DMDR) in children with advanced malignancy. Am Asso Cancer Res 1983;24:141.
2. Kamen B,  **N**, Lester C, Baylis F, Holcenberg J: Decreased folate associated with methotrexate polyglutamate accumulation in chronically treated monkeys. Am Asso Cancer Res, 1984.
3. Kamen BA, Streckfuss A,  **NJ**, Friedman HS, Bigner DD: Cellular pharmacokinetics in methotrexate in human medulloblastoma (TE671) in vivo. 6th International Conference on Brain Tumor and Research Therapy, 1985.
4. **N**, Streckfuss A, Kamen BA, Balis F, Lester C, Poplack D: Methotrexate, folate and CNS toxicity. 4th International Conference on Neurotoxicology of Selected Chemicals, 1985.
5. Pratt CB, Kamen B,  **N**, Sartain P, Champion J, Ragab A, Goren M, Wright R: Phase I study of cis-dichloro-trans-dihydroxy-bis (Isopropylamine) platinum IV (CHIP, JM9, NSC-256927) in patients with pediatric malignant solid tumors. Proc Am Soc Clin Oncol, 1986.
6. Pratt C, Kamen B,  **N**, Sartain P, Champion J, Ragab A: Phase I study of cis-dichloro-trans-dihydroxy-bis (Isopropylamine) platinum IV (CHIP, JM9, NSD‑256927) in pediatric patients. Proc Am Soc Clin Oncol, 1986.
7. **NJ**, Kamen BA, Craig J, McGuirt F, Capizzi RL, Sklar F, Coln D: Methotrexate (MTX) concentration in tumors following low-dose MTX. Presented at Am Asso Cancer Res, 1986.
8. Freeman A,  **N**, Ragab A, Ravindranath Y, Fernbach D, Ochs J: High dose alpha-2 interferon (IFN) in the treatment of childhood acute lymphocytic leukemia (ALL). Proc Am Soc Clin Oncol, 1987;6:164.
9. Ducore J, Mims E,  **N**, Kamen B: Low-dose "continuous" oral methotrexate (MTX) ± radiation therapy (RT) for pediatric CNS tumors: A Phase I/II Study. Proc Am Soc Clin Oncol 1987;6:68.
10. **N**, Buchanan G, Murphy SB, Yu A: Deoxycoformycin in the treatment of T-cell acute lymphoblastic leukemia (T-ALL) early in second remission. Proc Am Soc Clin Oncol 1987;6:152. Presented ASCO, 1987.
11. Boyett J, Pullen J, Jackson J, Vietti T, Borowitz M, Patterson R,  **N**, Crist W: Pre-B phenotype of childhood acute lymphocytic leukemia (ALL) has prognostic importance independent of cytogenetic and other known risk factors. A Pediatric Oncology Group (POG) Study. Blood 1987;70:198a.
12. Ruby JL, Argyle JC,  **N**, Van Dreal P: HPLC analysis of 6-mercaptopurine and metabolites. Presented at the XIII International Congress of Clinical Chemistry, The Hague, 1987.
13. **N**, Friedman H, Bigner D, Peryea X, Streckfuss A, Kamen BA: Methotrexate (MTX), schedule dependent drug accumulation. Presented at the Am Asso Cancer Res, 1988.
14. **N**, Bowman WP, Kamen BA: Prolonged intensive oral methotrexate (MTX) does not induce its own malabsorption. Presented at the Am Asso Cancer Res, 1989.
15. **N**, Bowman WP, Buchanan GR, Sartain P, Kamen BA: Treatment of childhood acute lymphoblastic leukemia (ALL): The incorporation of divided dose oral methotrexate (dMTX)/L-asparaginase (L-asp) and VP-16/Ara-C. Proc Am Soc Clin Oncol 1989;8:215. Presented ASCO, 1989.
16. **N**, Bowman WP, Buchanan GR, Sartain P, Kamen B: Treatment of acute lymphoblastic leukemia (ALL): The incorporation of divided dose oral methotrexate (dMTX)/L-asparaginase (L-asp) and VP-16/Ara-C. Presented at SPR, 1990.
17. Smith SD,  **N**, Shuster J, Land V, Rivera GK: Treatment of isolated central nervous system relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group Study Presented at Am Soc Clin Oncol, 1990.
18. Bash RO, Mustafa MM,  **N**, Buchanan G: Frequency and course of acquired hypogammaglobulinemia in pediatric cancer patients receiving cytotoxic chemotherapy. Presented at SPR, 1991.
19. Mustafa M, Weitman SD,  **NJ**, Bellini WJ, Timmons C, Siegel J: Measles inclusion-body encephalitis (MIBE) in immunocompromised (IC) patients (PTS): Report of diagnosis (DX) by PCR and treatment with intravenous (IV) ribavirin (RV) in 2 pts. Presented to the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy.
20. **N**, Bowman WP, Kamen B, Roach ES, Buchanan GR: Unexpected neurotoxicity in children with acute lymphoblastic leukemia receiving divided dose oral methotrexate. Accepted for Presentation at the Am Soc Clin Oncol, 1991.
21. Squires Jr RH, Zwiener RJ,  **NJ**, Andrews WA, Weinberg AG: Histiocytosis X Presenting with Hepatic Dysfunction.
22. **N**, McKenna R, Bowman WP, Kamen B, Shuster J, Buchanan G: Secondary acute myeloid leukemia (AML) in children with B-lineage acute lymphoblastic leukemia (ALL) treated with an epipodophyllotoxin. Presented at Am Soc Clin Oncol, 1992.
23. Katz JA, Everhart CR,  **NJ**, Lace L, Buchanan GR: Prevalence of hepatitis C antibody (anti-HCV) in long-term survivors of childhood cancer. Meeting Abstract 2nd International Conference on Long-term Complications of Treatment of Children and Adolescents for Cancer, 1992.
24. Mustafa M, Carlson L, Weitman S, Fort D, Bernini J, Aquino V,  **N**, Sandler E, Katz J, Rogers Z, McCracken G, Buchanan G: Cefepime (CP) vs ceftazidime (CZ) in the empiric treatment of febrile neutropenic children with malignancy (FNCM). Presented to the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 1993.
25. **N**, Bowman WP, Shuster J, Jacaruso D, Buchanan GR, Kamen B: An intensive oral methotrexate (dMTX) regimen protects against lymphoid marrow relapse in childhood acute lymphoblastic leukemia (ALL). Presented to the Am Soc Clin Oncol, 1994.
26. Wollner N,  **N**, Finlay J, Saigo P, Sklar C, Heller G, LaQuaglia M: Treatment of malignant non-testicular germ cell tumors (GCT) in children. Am Soc Clin Oncol 1993;12:a1456.
27. Sandler ES, Friedman DJ, Mustafa MM,  **NJ**, Bowman WP, Buchanan GR: Bone marrow transplantation (BMT) for epipodophyllotoxin-induced secondary acute myelogenous leukemia (AML). Presented at ASH, 1993.
28. Kennard BD, Stewart SM, Waller DA, Ruberu MR,  **NJ**, Bawdon RE, Buchanan G: Psychological and family factors in noncompliant adolescent oncology patients. Presented at the Annu Mtg Am Psycholog Asso, 1994.
29. Bernini JC, Mustafa MM,  **NJ**, Nicholson M, McHard K, Buchanan GR: Evaluation of the attenuated live virus measles vaccine (ALVMV) in children with cancer. Presented at the Am Soc Clin Oncol, 1994.
30. Mustafa M, Buchanan G,  **N**, Tkaczewski I, Ansari Q, Lipscomb M: Immune recovery in children with cancer (Ca) following cessation of chemotherapy. Presented to Infectious Diseases of American 32nd Annual Meeting, 1994.
31. **N**, Bowman WP, Shuster J, Jacaruso D, Buchanan GR, Kamen B: An intensive oral methotrexate (dMTX) regimen protects against lymphoid marrow relapse in childhood acute lymphoblastic leukemia (ALL). Presented at the Am Soc Clin Oncol, 1994.
32. Bernini J, Fort D, Griener J, Kane B, Chappell W,  **N**, Kamen B: The use of aminophylline for methotrexate-induced neurotoxicity: Evidence for adenosine receptor blockade. Presented at the Am Acad Cancer Res, 1995.
33. Smith A,  **N**, Kamen B: A case for the use of aminopterin (AMT) rather than methotrexate (MTX) in children with "high risk" acute leukemia based upon metabolic studies. Presented at Am Acad Cancer Res, 1995.
34. Felix C, Hosler M,  **N**, Masterson M, Wilson A, Lange B: ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related secondary leukemia in children. Presented at the Am Soc Clin Oncol, 1995.
35. Lauer SJ, Toledano S,  **N**, Munoz L, Manhoney D, Pullen J, Steuber CP, Shuster J, Camitta B:A comparison of early intensive methotrexate/mercaptopurine (MTX/MP) vs early intensive alternating chemotherapy for high risk acute lymphoblastic leukemia (HR-ALL). Presented at the Am Soc Clin Oncol, 1995.
36. Weitman S, Ochoa S, Sullivan J,  **N**, Pratt C, Vietti T, Harris M: Pediatric phase II cancer chemotherapy trials. Accepted for Slide Presentation, 1996.
37. Mahoney DH, Nitschke R, Lauer S, Shuster J,  **N**, Steuber CP, Camitta B: Neurotoxicity (NT) in children with acute lymphoblastic leukemia (ALL) receiving intensive methotrexate (MTX) schedules. A Pediatric Oncology Group (POG) Study. Meeting Abstract. Proc Annu Mtg Am Soc Clin Oncol 1996;15:A1082.
38. Mahoney DH, Nitschke R, Shuster J,  **N**, Lauer S, Pullen J, Steuber P, Camitta B: Comparison of intensive methotrexate/mercaptopurine (MTX/MP) vs low-dose repetitive (LD) MTX/MP for lower risk acute lymphoblastic leukemia (LR-ALL). A Pediatric Oncology Group (POG) randomized phase III study. Meeting Abstract. Proc, Annu Mtg Am Soc Clin Oncol 1996;15:A1081.
39. Hum MC, Smith AK, Lark RH, **, N**, Kamen BA: If methotrexate polyglutamates are the answer, is high dose MTX the solution? Meeting Abstract. Proc Annu Mtg Am Asso Cancer Res 1996;37:A2524.
40. Mustafa MM, Buchanan GR,  **NJ**, Lipscomb M, Tkaczewski I, Ansari Q: Immune recovery after cessation of chemotherapy (CT) in children with cancer (Ca). Meeting Abstract. Proc Annu Mtg Am Soc Clin Oncol 1996;15:A1776.
41. Farah RA,  **NJ**, Ewalt DH, Eshelman DA, Buchanan GR: Long-term effects of prior cyclophosphamide (CY) and ifosfamide (IFOS) therapy on lower urinary tract function of childhood cancer survivors. Meeting Abstract. Proc Annu Mtg Am Soc Clin Oncol 1997;16:A1891.
42. Farrow A, Wilson J, Marling-Cason M, Hum M,  **N**, Kamen BA: Phase I and pharmacokinetic (PK) trial of aminopterin (AMT) in adults and children with refractory malignancies. Meeting Abstract. Proc Annu Mtg Am Soc Clin Onco 1997;16:A735.
43. Felix CA, Walker AH, Lange BJ, Williams TM,  **NJ**, Cheung N-KV, Lovett BD, Nowell PC, Blair IA, Rebbeck TR: Genetic predisposition to treatment-related leukemia: Association of CYP3A4 genotype with epipodophyllotoxin-induced cases. Am Soc Hematol, 1998.
44. Mantadakis E, Smith A K, Ratliff A F,  **N J**, Kamen B A: Methotrexate Polyglutamation Does Not Correlate with Event-Free Survival in Children with B-Lineage Acute Lymphoblastic Leukemia (Meeting abstract). Proc Annu Mtg Am Soc Clin Oncol 1999, 18:2182.
45. Mantadakis E, Herrera L, Leavey P, Bash RO,  **NJ**, Kamen BA: Fractionated cyclophosphamide and etoposide for children with advanced or refractory solid tumors: A Phase II Window Study. Presented Am Soc Clin Oncol 19:2000 (abstract 2332).
46. Aquino V, Weitman S,  **N**, Blaney S, Bernstein M: Phase 1 Study of Tirapazamine and Cyclophosphamide in Children with Refractory Solid Tumors. Proc Annu Mtg Am Soc Clin Oncol 19:2000 (abstract 787).
47. Megason G, Weitman S, Blaney S,  **N**, Kuhn J, Pullen J, Bernstein M: A Trial of 6-Hydroxymethylacylfulvene (MGI-114) in Children with Solid Tumors, a Pediatric Oncology Group (POG) Phase 1 Cooperative Agreement Study. Proc Annu Mtg Am Soc Clin Oncol 19:2000, (abstract 781).
48. Wacker P,  **NJ**: Lack of significant correlation between plasma methotrexate (MTX), red blood cells (RBC) MTX and RBC folate levels with EFS in children with B-precursor ALL. Study Presented A Pediatric Oncology Group Study, Am Soc Hematol, 2001.
49. Blanco JG, Edick MJ, Shuster JJ, Dervieux T, Amylon MD, Bash RO, Behm FG, Camitta BM, Pui C-H, Raimondi SC,  **NJ**, Hancock ML, Relling MV: Genetic polymorphisms in NQO1 and CYP3A4 in children with treatment-related acute myeloid malignancies. Study Presented ASH Annual Meeting, The Children’s Oncology Group.
50. Molmenti EP, Nagata D, Roden J, Squires R, Molmenti H, Casey D, Fasola C, Lopez MJ,  **N**, McPhail W, D’Amico L, Goldstein R, Levy M, Fasola C, Andersen J, and Klintman: Incidence, management, and outcome of posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Transplant Proc 2001 Feb-Mar;33(1-2):1727.
51. Bomgaars L, Geyer J, Franklin J, Arceci R J,  **N**, V Dahl G, Klenke R, Berg S, Blaney S: A phase I study of intrathecal liposomal cytarabine (DepoCyt) in pediatric patients with advanced meningeal malignancies. Proc Annu Mtg Am Soc Clin Oncol 22:2002 (abstract 433).
52. Barredo J C, Lawer S, Billet A, Marymount M, Camitta B,  **N**, et al: Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: A pediatric oncology group study. Proc Annu Mtg Am Soc Clin Oncol 22:2003 (abstract 3200).
53. Bowers, D C, Gargan L, Kapur P,  **N**, et al: Study of the MIB-1 labeling index as a predictor of tumor progression in pilocytic astrocytomas in children and adolescents. Proc Annu Am Soc Clin Oncol 22:2003 (abstract 445).
54. Borowitz M J, Pullen DJ,  **N**, et al: Comparison of diagnostic and relapse flow cytometry phenotypes in childhood ALL: Implications for residual disease (MRD) detection. Am Soc Hematol, Nov 2004 (abstract 451).
55. Davies S M, Borowitz M, Devida M,  **N**, et al: Pharmacogenetics of minimal residual disease response in children with acute lymphoblastic leukemia (ALL). Am Soc Hematol, 104:2004 (abstract 1091).
56. Aquino V, Leavey P, Hoffman T, Bowers D, Scothorn D, Bash R,  **N**: Availability of phase 1 therapies to pediatric oncology patients with refractory or recurrent malignancies. Proc Annu Mtg Am Soc Clinic Oncol, 2005 (abstract 8531).
57. Gargan L, Mulne A, Elterman R, Weprin B,  **N**, et al: Survival for children with medulloblastoma following tumor recurrence or progression. Am Soc Hematol, Vol 23:16, 2005.
58. Leavey P, Bowers D C, Aquino V, Bash R, Tomlinson G, Hoffman T, Griener J, Frawley W,  **N**, et al: Pharmacokinetics of fractionated cyclophosphamide (CY) in children with recurrent malignancies. Am Soc Hematol, 2005. Vol 23:16.
59. Wright J A, Reimold S C,  **N J**, Turoff A, Brooks S, Eshelman D, Oeffinger K C: Evaluation for cardiac toxicity with MRI in young adult survivors of acute lymphoblastic leukemia (ALL). Proc Annu Mtg Am Soc Clinic Oncol, 2006, Vol 24:185.
60. Matloub Y, Angiolillo A, Bostrom B, Hunger S P, Nachman J, Sather H, Carroll W L,  **N**, Gaynon P S: Double Delayed Intensification (DDI) Is Equivalent to Single DI (SDI) in Children with National Cancer Institute (NCI) Standard-Risk Acute Lymphoblastic Leukemia (SR-ALL) Treated on Children’s Cancer Group (CCG) Clinical Trial 1991 (CCG-1991). Am Soc Hematol, Nov 2006, Vol 108:146.
61. Borowitz M J, Devidas M, Bowman W P, Carroll W L, Chen I, Harvey R, Hunger S, Martin P L, Pullen J, Viswanatha D, Willman C L,  **N**, Camitta B: Prognostic Significance of Minimal Residual Disease (MRD) in Childhood B-Precursor ALL and Its Relation to Other Risk Factors. A Children’s Oncology Group (COG) Study. Blood (ASH Annual Meeting Abstracts), Nov 2006, Vol 108:219.
62. Schultz K R, Aledo A, Bowman W P, Slayton W P, Sather H, Willman C L, Gastier-Foster J M, Heerema N A, Carroll A J, Borowitz M J,  **N**, Hunger S J, Carroll W L: Minimal Toxicity of Imatinib Mesylate in Combination with Intensive Chemotherapy for Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) in Children: A Report of the Children’s Oncology Group (COG) AALL0031 Protocol for Very High Risk ALL. Blood (ASH Annual Meeting Abstracts), Nov 2006, Vol 108:283.
63. Nguyen K, Cheng S, Raetz E, Sather H, Carroll W L,  **N**, Hunger S P, Gaynon P, Loh M L: Factors Influencing Survival after Relapse from Childhood ALL: A Children’s Oncology Group Study. Blood (ASH Annual Meeting Abstracts), Nov 2006, Vol 108:1855.
64. Maloney K W, Larsen E, Mattano L A, Friedmann, Devidas M, Sather H, Hunger S,  **N**, Carroll W L: Increased Infection-Related Mortality for Children with Down Syndrome (DS) in Contemporary Children’s Oncology Group (COG) Acute Lymphoblastic Leukemia (ALL) Clinical Trials. Blood (ASH Annual Meeting Abstracts), Nov 2006, Vol 108:1865.
65. Raetz E A, Borowitz M J, Devidas M, Hunger S P,  **N**, Bruce Camitta, Paul S. Gaynon, and William L. Carroll: Outcomes of Children with First Marrow Relapse: Results from Children’s Oncology Group (COG) Study AALL01P2. Blood (ASH Annual Meeting Abstracts), Nov 2006, Vol 108:1871.
66. **N**, Borowitz M J, Devidas M, Martin P L, Pullen J, Hunger S P, Carroll W L, Camitta B: Changes in the Delivery of Standard Chemotherapeutic Agents during Induction Affect Early Measures of Minimal Residual Disease (MRD): POG 9900 for Patients with B-Precursor Low and Standard Risk ALL: Blood (ASH Annual Meet**in**g Abstracts), Nov 2006, Vol 108:2272.
67. Cox, J, Metcalf P, Seigel J,  **N**: Invasive healthcare-associated (HA) environmental fungal infections (EFI) in pediatric oncology (ONC) patients (PTS) are an ever-present risk. Jour of Clinc Oncol, 2007, Vol 25:19631.
68. Wright J A, Reimold S, Turoff A, Brooks S, Huet B, Eshelman D,  **N**, Oeffinger K: Long-term cardiac outcomes following low-dose anthracycline exposure**.**  Jour of Clinc Onocl**,** 2007, Vol 25:9519.
69. Czuchlewski D R, Harvey RC,  **N**, et al: Quantitative RT-PCR for Expression of a Small Subset of Genes Identifies Novel Prognostic Subgroups in High-Risk Pediatric Precursor B-Cell Acute Lymphoblastic Leukemia (HR-ALL): Clinical Applicability of Gene Expression Microarray Data from Children's Oncology Group Trials. Jour Am Soc Hematology, Nov 2008 (abstract 1514).
70. Harvey R C, Chen I M,  **N**, et al: Identification of Novel Cluster Groups in High-Risk Pediatric B-Precursor Acute Lymphoblastic Leukemia (HR-ALL) by Gene Expression Profiling: Correlation with Clinical and Outcome Variables. a Children's Oncology Group (COG) Study. Jour Am Soc Hematology, Nov 2008 (abstract 2256).
71. Matloub Y, Bostrom B C, Hunger S, Angiolillo A, Cole C, Thompson B, Devidas M, Heerema N, AL M K, Buckley P, Carroll W,  **N**, et al: Escalating Dose Intravenous Methotrexate without Leucovorin Rescue during Interim Maintenance Is Superior to Oral Methotrexate for Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): Children's Oncology Group Study 1991. Jour Am Soc Hematology, Nov 2008 (abstract 9).
72. Matloub Y, Gaynon P S, Jayabose S, Bostrom B, Hunger S, Angiollio A, Devidas M, Linda S, Carroll W, **, N**, et al: Bone Marrow (BM) Minimal Residual Disease (MRD) at End of Induction and Interim Maintenance Is Highly Predictive of Outcome in Children with Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Treated on the Children's Oncology Group Study 1991. Jour Am Soc Hematology, Nov 2008 (abstract 701).
73. Mattano, L A, Nachman J B, Devidas M,  **N**, et al: Increased Incidence of Osteonecrosis (ON) with a Dexamethasone (DEX) Induction for High Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report from the Children's Oncology Group (COG). Jour Am Soc Hematology, Nov 2008 (abstract 898).
74. Schultz, K R, Bowman W P,  **N**, et al: Philadelphia Chromosome Negative (Ph-) Very High Risk (VHR) Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents: The Impact of Intensified Chemotherapy on Early Event Free Survival (EFS) in Children's Oncology Group (COG) Study AALL0031. Jour Am Soc Hematology, Nov 2008 (abstract 911).
75. Dunsmore K, Devidas M, Borowitz M J,  **N**, Hunger S P, Carroll W L, Camitta B M: Nelarabine in combination with intensive modified BFM AALL00P2: A pilot study for the treatment of high risk T-ALL a report from the Children's Oncology Group.J Clin Oncol, May 2008 (abstract 1864 and 10002).
76. Maloney K, Carroll W L, Carroll A, Devidas M, Hunger S P, Martin P L, Willman C L,  **N**, Whitlock J, Camitta B M: Comparison of the biology of Down syndrome (DS) acute lymphoblastic leukemia (ALL) and non-DS ALL: Children's Oncology Group (COG) study P9900.Clin Oncol 26: 2008.
77. Borowitz M J, Devidas M, Hunger S P, Carroll W L, Linda S, Pullen D J, Viswanatha D, Willman C L,  **N**, Camitta B M: Prognostic significance of end consolidation minimal residual disease (MRD) in childhood acute lymphoblastic leukemia(ALL): a report from the Children's Oncology Group(COG). Clin Oncol**,** 26: 2008.
78. Chang B H, Willis S G, Stork L, Hunger, S P, Carroll W L, Camitta B M,  **N J**, Drucker B J, Schulta K R: Mutational Analysis of BCR-Abl From Subjects with Relapsed Ph+ALL Treated on the COG Protocol AALL0031 & nbsp; A Report From the Children’s Oncology Group. (ASH Annual Meeting Abstracts), Dec 2009.
79. Horton T M, Sposto R, Brown P, Reynolds C P, Hunger S P,  **N J,** Raetz E A, Carroll W L, Arceci R J, Borowitz M J, Gaynon P S, Gore L, Jeha S, Maurer B J, Siegel S E, Biondi A, Kearns P R, Narendran A, Silverman L B, Smith M A, Zwaan M C, Whitlock J A: Toxicity Assessment of Molecularly Targeted Drugs Incorporated into Multiagent Chemotherapy Regimen for Pediatric Acute Lymphocytic Leukemia (ALL): Review form an International Consensus Conference. Pediatr Blood Cancer, Dec 2009.

**Additional abstracts available on request**